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Abstract 
Glioblastoma multiforme (GBM) is a destructive brain cancer that results in death 12 to 
15 months after diagnosis.  The purpose of this retrospective study was to determine if 
variations in tumor size at diagnosis, treatment options, and survival rate occur in GBM 
patients living in urban and rural areas of the United States.  Using the behavior model of 
health services as the theoretical framework, this study used secondary data sets of GBM 
cases reported from 1988 to 2011 from the Surveillance, Epidemiology, and End Results 
program.  Tumor size was measured in millimeters; treatment was evaluated by 
ascertaining the number of GBM patients who had surgical resection of their tumors, 
radiation, and chemotherapy; and survival rate was evaluated using Cox Regression 
analysis.  With a sample size of 33,202 cases, data were examined using descriptive and 
multivariable analyses with SPSS.  Results showed statistically significant differences in 
tumor size at diagnosis in rural patients compared to urban patients (p = 0.0085; p = 
0.018), more urban patients were treated with radiation compared to rural patients (p < 
0.001), and rural patients had poorer survival rates than urban patients (p < 0.001).  
Finally, when controlling for region, race, age, gender, education, and income, longer 
survival time was associated with urban status, female cases, and higher family income (p 
< 0.0001), and greater age was associated with reduced survival time (p < 0.0001).  Study 
results could promote positive social change by identifying predictive variables 
associated with health outcomes of GBM patients.  It may also educate providers on the 
risk of rurality of patients diagnosed with GBM, and inform lawmakers responsible for 
the creation of healthcare policy and the equitable allocation of healthcare resources.
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Chapter 1: Introduction to the Study  
Glioblastoma multiforme (GBM) is a malignant brain neoplasm known for its 
destructive ability to invade healthy brain tissue at an accelerated rate, resulting in death 
12 to 15 months after diagnosis (Holland, 2000).  For this reason, Holland (2000) has 
referred to GBM as “the terminator” (p. 6242).  Once diagnosed, patients typically 
undergo surgery for tumor removal followed by radiation and chemotherapy (Jelsma & 
Bucy, 1967).  Despite these treatment modalities, there are few long term GBM 
survivors.  Research has focused on finding effective and novel therapies aimed at 
prolonging life such as immunotherapy, gene therapy, and viral therapy (Holland, 2000).  
Immunotherapy research has focused on whether or not the body’s immune system 
responds to the presence of a GBM tumor, referred to as a glioblastoma-specific immune 
response (Haque, Nagarkatti, Nagarkatti, Banik, & Ray, 2010).  Gene therapy research 
has focused on switching out the defective portion of a gene causing GBM for a 
functional portion of the gene (Kwiatkowska, Nandhu, Behera, Chiocca, & Viapiano, 
2013).  Moreover, viral therapy research involves the creation of a killer virus that 
destroys cancer cells (Holland, 2000; Shah & Markert, 2004).   
Despite the abundant research from a multitude of perspectives, no one really 
knows what causes GBM.  Research has identified three specific risk factors for brain 
tumors in general: exposure to ionizing radiation, rare genetic mutations, and family 
history (Bondy & Ligon, 1996; DeAngelis, 2001; Fisher, Schwartzbaum, Wrensch, & 
Wiemels, 2007; Inskip, Linet, & Heineman, 1995).  Unfortunately, only a very small 
proportion of brain malignancies are attributable to these risk factors (Fisher et al., 2007).  
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Other potential risk factors like cell phone use, smoking, and environmental exposures 
have been explored in the development of brain neoplasms.  However, these studies were 
not definitive (Bondy et al., 2008; Connelly & Malkin, 2007; Gomes, Al Zayadi, & 
Guzman, 2011).  What  is known is that in the United States, cancer incidence varies 
from state to state (Centers for Disease Control and Prevention, 2013).  In 2011, the age-
adjusted brain and spinal tumor incidence for the United States was 6.4 per 100,000 
people (all races), and state incidences ranged from 3.4 to 10.3 (Howlader et al., 2014).  
In 2011, the age-adjusted incidence for GBM was 4.3 per 100,000 people (Howlader et 
al., 2014).  In this introductory chapter, I present a comprehensive overview for this 
study; that is, an examination of the urban/rural variations of a specific brain tumor 
known as GBM.  The following topics specific to this study will be covered: background, 
problem statement, purpose, theoretical foundation, major assumptions, scope and 
delimitations, limitations, and significance. 
Background of the Study 
Cancer is a significant health issue worldwide.  In 2012, over 14 million people 
worldwide were diagnosed with cancer with a projected increase to 24 million by 2035 
(Ferlay et al., 2013).  An interesting pattern of brain cancer and various nervous system 
cancers have emerged in the United States: higher rates in the southeast, northwest, and 
midwest, and lower rates in the Rocky Mountains, northeast, and southwest (Devesa et 
al., 1999). 
One of the most pressing issues facing the field of public health is trying to 
ascertain what makes some people healthy while other people are unhealthy.  When 
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attempting to determine the factors that influence the health of people, the traditional 
perspectives are categorized as follows: biological, environmental, lifestyle, 
psychosocial, and access to health-related services (Turnock, 2009).  The combination of 
these factors is known as the determinants of health, and the interrelationships of these 
factors contribute to the health or lack of health for individual and populations (Turnock, 
2009; United States Department of Health and Human Services, 2014).  Access to health 
services and the quality of those health services influence health.  In the 1980s, a great 
deal of research examined access to healthcare resources from an urban versus rural 
perspective.  Studies showed that rural areas had fewer providers and hospitals than urban 
areas (Reschovsky and Staiti, 2005; Ricketts, 2000).  Consequently, rural populations had 
less access to healthcare, used less healthcare resources, and paid more for healthcare 
(Hartley, 2004).  Newer urban/rural research has focused on the health of populations 
from an environmental perspective, and the resultant effect on health behaviors (Arcury 
et al., 2005; Goodman, Fisher, Stukel, & Chang, 1997; Higginbotham, Moulder, & 
Currier, 2001).  In this study, I will examine variables that affect health and potentially 
identify factors that may contribute to different health outcomes for urban and rural 
residents.  Urban and rural environments will be thoroughly discussed in Chapter 2. 
A tumor or neoplasm is defined as an abnormal tissue mass that can be either 
benign or malignant (National Cancer Institute, n.d.).  More specifically, a neoplasm of 
the brain is defined as a mass of abnormal cells growing in the brain, and a malignant 
brain tumor is one that is considered cancerous because the growth of abnormal cells are 
out of control and destructive to healthy brain tissue (National Cancer Institute, n.d.).  
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While most malignant tumors metastasize or spread to other body parts, malignant brain 
tumors are not metastatic.  Rather, malignant brain tumors infiltrate healthy brain tissue 
and cause massive destruction (National Cancer Institute, 2009). 
The most common malignant brain tumor in adults is known as a GBM (National 
Cancer Institute, 2009, 2012). Patients with GBM may experience any of the following 
conditions: persistent headaches, visual disturbances, mood and/or personality changes, 
seizures, changes in ability to think, loss of appetite, vomiting, and/or difficulty with the 
spoken word (Brandes et al., 2008; Davis & Stoiber, 2011; Fox, Lyon, & Farace, 2007; 
Nolan & Gavrilovic, 2010).  Patients who complain of the aforementioned symptoms will 
usually undergo specific radiologic procedures known as computed tomography (CT) 
and/or magnetic resonance imaging (MRI; Fink & Fink, 2013).  CT and MRI scans can 
only ascertain that a brain tumor exists.  The way to determine the type of brain tumor is 
through biopsy or tumor removal (Davis & Stoiber, 2011).  The prognosis is quite poor 
for patients diagnosed with GBM; that is, once diagnosed, median survival is 12 to 15 
months from diagnosis (Deorah, Lynch, Sibenaller, & Ryken, 2006). 
In any given cancer diagnosis, the size of the tumor is a significant prognostic 
indicator of survival; that is, a smaller tumor size is a better prognosis for survival than a 
larger tumor.  In the case of GBM, patient symptomatology is usually related to a larger 
tumor size found at diagnosis.  It is not uncommon for GBM patients to be asymptomatic 
until the tumor reaches an enormous size (Iacob & Dinca, 2009).   
Another prognostic indicator of survival is the type and extent of treatment 
options offered to patients diagnosed with GBM.  Since the GBM tumor is aggressively 
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fast-growing, highly vascular, and invasive in nature, treatment by necessity usually 
includes surgery followed by adjuvant therapies of radiation and chemotherapy 
(Hentschel & Lang, 2005).  Surgery is usually the initial intervention in treatment of 
GBMs, and the question most often raised is the degree of surgical aggressiveness 
(Hentschel & Lang, 2003).  The overall goals of surgical resection are three-fold: 
diagnostic confirmation of GBM, symptom management, and improving overall survival.  
According to Hentschel and Lang (2003), diagnostic confirmation relies on obtaining 
adequately sized tissue samples for accurate histological diagnosis.  Symptom 
management involves a thorough understanding of the neurological symptoms caused by 
GBMs.  Hentschel and Lang noted that GBM tumors affect patients in two separate and 
distinct ways:  diffuse neurological symptoms or focal neurological deficits.  Diffuse 
neurological symptoms result from increased intracranial pressure that is due to the size 
of the tumor and the edema (swelling) that it produces (Ammirati, Vick, Liao, Ciric, & 
Mikhael, 1987; Fadul et al., 1988; Lacroix et al., 2001; Prabhu, 2007; Sawaya et al., 
1998).  Symptoms of increased intracranial pressure are headache, nausea, vomiting, 
blurred vision, alteration in the level of consciousness, and/or seizures.  Examples of 
focal neurological deficits would be a gradual decline in memory, judgment, language 
problems, personality changes, and mobility and sensory changes (Ammirati et al., 1987; 
Fadul et al., 1988; Prabhu, 2007; Sawaya et al., 1998).  In most other areas of oncologic 
tumors, the goal of surgery is complete tumor removal along with removal of large areas 
of normal tissue surrounding the tumor (Hentschel & Lang, 2003).  However, the 
invasive nature of GBMs prevents the neurosurgeon from being able to completely 
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remove the entire tumor as well as normal brain tissue (Hentschel & Lang, 2003; 
Sahebjam, McNamara, & Mason, 2012).  Surgical resection helps to reduce the diffuse 
neurological symptoms caused by GBMs.  In contrast, surgical resection may or may not 
improve focal neurological symptoms.  According to Stummer, van den Bent, and 
Westphal (2011), the extensiveness of tumor removal is considered one of the strongest 
prognostic factors in prolonging survival, decreasing tumor size, and managing 
symptoms in GBM patients.   
The hypothesis of this particular study is that rural GBM patients will have larger 
tumors, experience fewer surgical resections, undergo fewer adjuvant therapies of 
radiation and chemotherapy, and have decreased survival when compared to their urban 
counterparts.  This hypothesis is based on the following assumptions: rural populations 
have limited access to health services, travel greater distances to access health services, 
are in poor health, and have limited financial means. 
Problem Statement 
The impact of cancer on the United States population is multifaceted.  According 
to Gosschalk and Carozza (2003), studies have demonstrated variations in incidence, 
mortality, and staging of particular cancers when examining the variables of race, 
geographic areas of the United States, gender, and age.  GBM is an aggressive brain 
cancer with an abysmal mortality of 12 to 15 months once diagnosed (Ng, Kesari, Carter, 
& Chen, 2011; Wen & Kesari, 2008).  By the time GBM patients are diagnosed, their 
tumor size is quite large, and the treatment options of surgery, radiation, and 
chemotherapy are used to lengthen survival time beyond a year. 
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Past GBM research has focused on environmental and occupational exposures 
with ambiguous results (Connelly & Malkin, 2007; Gomes et al., 2011).  Population-
based studies have examined the incidence of brain tumors and survival rates from a 
gender perspective (Ohgaki et al., 2004; Ohgaki & Kleihues, 2005).  However, there are 
no studies that have examined the occurrence and survivability of GBM tumors from the 
geographic perspective of living in rural versus urban regions.  Consequently, the nature 
of the relationship between living in urban versus rural regions and GBM is unclear.  
Given the high mortality rates of GBM patients, if there is an association linking place of 
residence and survival rates of GBM patients, then reduction of the barriers and 
disparities that contribute to these negative outcomes might be achieved. 
Significance 
Anyone can develop cancer. Despite modern technology and cutting-edge 
research to reduce cancer incidence and mortality, cancer prevalence is on the rise due to 
an aging population (American Cancer Society, 2012; Gosschalk & Carozza, 2003).  The 
literature review in Chapter 2 provides significant and noteworthy information.  For 
example, the relationship between urban and rural populations and early cancer detection 
is uncertain (Blair et al., 2006).  Additionally, patients diagnosed with GBM have 
unusually high mortality rates coupled with low survival rates owing, in part, to delays in 
diagnosis and treatment (Mathiesen, Paredo, & Lönn, 2011).  Furthermore, the GBM 
tumor itself is characterized by aggressive growth and extensive infiltrative and invasive 
vasculature.  While some studies have examined the association of increased incidence of 
certain cancers in rural populations (Gosschalk & Carozza, 2003; Singh, Williams, 
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Siahpush, & Mulhollen, 2011), there are no studies that have investigated whether 
rurality is a prognostic indicator for patients diagnosed with GBM. 
Purpose of the Study 
The purpose of this retrospective, quantitative study is to ascertain whether there 
are variations in tumor size, treatment options, including surgical resection and adjuvant 
therapies of radiation and chemotherapy, and survival rates between rural and urban 
residents diagnosed with GBM.  This study will use secondary data obtained from the 
Surveillance and Epidemiology End Results (SEER) database.  Rural and urban residents 
are defined as men and women who are 20 years of age and older.  Urban and rural areas 
will be based exclusively on the SEER definition of using rural-urban continuum codes 
(RUCCs) to distinguish urban from rural regions.  This classification system 
differentiates urban counties by population size.  Alternatively, rural counties are 
differentiated by the degree of growth, development, expansion, and proximity to an 
urban county.  This study will use the SEER database to ascertain if variations in tumor 
size, treatment options, and survival rates exist among urban and rural area GBM patients 
living in the United States. 
Nature of the Study 
The focus of this cohort study is on newly diagnosed GBM adult patients 20 years 
of age and older.  Participants will be drawn from the SEER database from 1988 through 
2011.  From a quantitative perspective, tumor size will be measured in centimeters as 
reported in the SEER database.  Patients with GBM tumors undergo surgery followed by 
radiation therapy and chemotherapy (Hentschel & Lang, 2003).  Surgery is the first 
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course of treatment, and there is a great deal of controversy in the neurosurgical 
community concerning the degree of surgical resection; that is, biopsy versus surgical 
resection (Hentschel & Lang, 2005; Koul, Dubey, Torri, Kakumanu, & Goyal, 2012).  
Some neurosurgeons initially prefer to perform a biopsy while other neurosurgeons 
advocate for aggressive surgical resection.  Over the last 2 decades, studies have 
demonstrated the value of aggressive resection of GBMs by affecting overall survival 
(Ammirati et al., 1987; Hentschel & Lang, 2003; Keles, Anderson, & Berger, 1999; 
Lacroix et al., 2001; Sawaya et al., 2001).  It is customary to follow aggressive surgical 
resection with adjuvant therapies of radiation treatment and chemotherapy.  
Groundbreaking research has shown definitively that surgery followed by radiation 
therapy and chemotherapy has increased survival from a little more than 3 months to 7 to 
12 months (Stupp et al., 2005).  Finally, survival rates, otherwise known as survival 
statistics, show the proportion of patients who survive cancer for a specified amount of 
time.  This study will use a common cancer statistic known as the 5-year survival rate 
(Centers for Disease Control, 2014), or the proportion of patients who remain alive 5 
years from initial diagnosis (Mayo Clinic, 2013).  
Differentiating rural from urban areas is critical to this study.  As a way of 
discerning an urban region from a rural region, the United States Department of 
Agriculture (2013) developed a classification system comprised of nine codes 
corresponding to population size and adjacency to a metropolitan area.  Every county in 
the United States is consigned to one of the nine codes referred to as RUCCs.  The SEER 
database uses the RUCC system. 
10 
 
 
Research Questions and Hypotheses 
The following research questions and hypotheses form the basis for this 
quantitative study: 
Research Question 1: When comparing urban and rural patients with GBM, is 
there a significant difference in GBM tumor size at diagnosis? 
H01: When comparing urban and rural patients with GBM, there is no significant 
difference in GBM tumor size.  
H11: When comparing urban and rural patients with GBM, there is a significant 
difference in GBM tumor size. 
Research Question 2: When comparing urban and rural patients with GBM, is 
there a significant difference in the number of patients who experienced surgical 
resections? 
H02: When comparing urban and rural patients with GBM, there is no significant 
difference in the number of patients who experienced surgical resections. 
H12: When comparing urban and rural patients with GBM, there is a significant 
difference in the number of patients who experienced surgical resections. 
Research Question 3: When comparing urban and rural patients with GBM, is 
there a significant difference in the number of patients who experienced the adjuvant 
therapies of radiation treatment and chemotherapy? 
H03: When comparing urban and rural patients with GBM, there is no significant 
difference in the number of patients who experienced the adjuvant therapies of radiation 
treatment and chemotherapy. 
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H13: When comparing urban and rural patients with GBM, there is a significant 
difference in the number of patients who experienced the adjuvant therapies of radiation 
treatment and chemotherapy. 
Research Question 4: When comparing urban and rural patients with GBM, is 
there a significant difference in survival rates? 
H04: When comparing urban and rural patients with GBM, there is no significant 
difference with survival rates. 
H14: When comparing urban and rural patients with GBM, there is a significant 
difference in survival rates. 
Research Question 5:  In the study population of GBM patients, is there a 
significant difference in survival rates when controlling for region, race, age, sex, 
educational level, and median family income? 
H05: In the study population of GBM patients, when controlling for region, race, 
age, sex, educational level, and median family income, there is no significant difference 
in survival rates.  
H15: In the study population of GBM patients, when controlling for region, race, 
age, sex, educational level, and median family income, there is a significant difference in 
survival rates.  
 The sample was drawn from the SEER database and consisted of subjects 
diagnosed with GBM with the following attributes: (a) adult males and females, 20 years 
of age and older, (b) urban or rural place of residence, (c) age at diagnosis, (d) year of 
diagnosis between 1988 and 2011, (e) tumor size, (f) race/ethnicity: all races/ethnicities 
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reported, (g) surgical resection, (h) adjuvant therapies: radiation therapy and 
chemotherapy, and (i) survival time: 5 years after diagnosis.  The data were analyzed 
using the latest version of SPSS.  For the purpose of this study, the independent variable 
was region, apportioned to urban and rural regions using RUCCs.  The level of 
measurement of the independent variable was nominal.  There were four dependent 
variables: tumor size at initial diagnosis, surgical resection, adjuvant therapies of 
radiation treatment and chemotherapy, and survival rate. The level of measurement for 
tumor size was ordinal; that is, tumor size was measured in centimeters. Ordinal 
measurements assign observations into categories that can be put into rank order and do 
not quantify differences (Gerstman, 2008, p. 5).  Since rank orders do not quantify 
differences, conditions of normality and equal variance are absent.  Thus, a 
nonparametric statistic was used.  Data analysis for the first research question used the 
independent samples t test.  For the second (surgical resection) and third research 
questions (adjuvant therapies of radiation treatment and chemotherapy), the level of 
measurement was nominal.  GBM patients were identified as to whether or not they 
experienced surgical resections (yes/no), radiation treatment (yes/no), and chemotherapy 
(yes/no).  Data analysis for surgical resections, radiation treatment, and chemotherapy 
used the independent samples t test.  The fourth research question involving survival rate 
used a combination of Kaplan-Meier for univariate analysis and Cox proportional hazards 
(regression analysis) for multivariate analysis of survival differences between groups 
(metropolitan and nonmetropolitan).  Finally, the fifth research question used multiple 
regression modeling to determine the best predictive model based on the independent 
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variables of region, age, marital status, race, educational level, and family income in the 
study population of GBM cases (Klein, 2010; Klein, Ji, Rea, & Stoodt, 2011). 
Theoretical Base 
The theoretical framework used for this study was Andersen’s behavior model of 
health services use developed in the late 1960s (Andersen, 1995).  With a major focus on 
accessing health care, this model has undergone several iterations over the last 40 years.  
The original focus was on the family unit while the later models explored the individual.  
Regardless of the focus, the model sought to understand how and why health services 
were used as well as any factors that contributed to or hindered one’s access to medical 
care.  Andersen (1995) postulated that there were three essential factors that affected 
one’s use of health care services or access to medical care:  predisposing factors, enabling 
factors, and need factors.  Predisposing factors are defined as demographic features of 
human beings like age, gender, ethnicity, education level, occupational background, and 
ethnicity, and basic health beliefs (Andersen, 1995). Enabling factors are viewed as 
resources that contribute to one’s use of health services like income, insurance coverage, 
and the geographic region where one lives (Andersen, 1995).  Finally, need factors are 
defined as the most immediate reasons why an individual would seek health care like 
illness or trauma (Andersen, 1995).  Placing this study within the context of the 
theoretical foundation, it is possible that because of the predisposing characteristics and 
enabling resources specific to rural patients, delays in accessing health care resources 
might lead to larger tumor size, decreasing KPS, and poorer survival rates of rural GBM 
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patients.  This model will be further explored in Chapter 2.  Figure 1 shows the health 
behavior model by Andersen. 
 
 
Figure 1. The health behavior model as put forth by Andersen. Andersen, R.M. (1995).  
Revisiting the behavioral model and access to medical care: Does it matter?  Journal of 
Health and Social Behavior, 36(1), 1-10. Reprinted with permission (Appendix B). 
 
For this study, the following constructs of the health behavior model form the 
basis of data collected from the SEER database: 
• Health Care System: Location, that is, rural versus urban areas using the 
RUCCs used by the SEER database. 
• Predisposing characteristics: Demographic factors such as age, gender, 
and race obtained through the SEER database.  Educational level or 
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median family income is not available from the SEER database but is 
available at the county level.  For this study, educational level and median 
family income were obtained from county data. 
• Enabling resources: Financial resources, insurance coverage, rurality, or 
the degree of urban versus rural locations (distance from healthcare 
resources, access to transportation as defined by RUCC in the SEER 
database). 
• Need: The reason that causes the individual to seek healthcare services 
(diagnosis of GBM) and measured by tumor size, treatment options, and 
survival rates from the SEER database.  Please see Table 1. 
Table 1 
 
HBM Constructs and Relationship to Study Variables 
 
HBM construct Description           Database Study variable 
Health care system Location SEER: RUCC Codes (urban or 
rural) 
Independent 
Predisposing 
characteristics 
Demographic data *SEER: Age-Sex-Race 
*County Data: Educational    
level and median family 
income 
Dependent 
Enabling resources *Financial data 
*Insurance  
*Rurality 
*SEER: RUCC Codes 
*County Data: median family 
income and insurance 
Independent 
Dependent 
Need Diagnosis of GBM SEER: tumor size-treatment 
options-survival rate-
mortality rate 
 
Dependent 
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Definition of Terms 
 Glioblastoma Multiforme (GBM): A malignant brain tumor known as a Grade-4 
glioma. 
 Glioma: A broad term that describes a tumor that originates from glial cells 
specific to the brain. Glial cells provide support and protection to the nervous system. 
 Rural-urban classification code:  The SEER database uses the geographical 
region known as a county to define urban and rural regions.  An urban county is defined 
by population size.  Alternatively, a rural county is defined by how close it is to an urban 
area.  See Table 2 below. 
Table 2 
 
Urban and Rural Continuum Codes 
 
Metropolitan counties Definition 
Code  
1 Metro area with 1 million or more people 
2 Metro area with 250,000 to 1 million people 
3 Metro area with fewer than 250,000 people 
Nonmetropolitan 
Counties 
  
Code  
4 Adjacent to metro area, 20,000 or more people 
5 Nonadjacent to metro area, 20,000 or more people 
6 Adjacent to metro area, 2,500 to 19,999 people 
7 Nonadjacent to metro area, 2,500 to 19,999 people 
8 
9 
Adjacent to metro area, < 2,500 people or totally rural 
Non adjacent to metro area, < 2,500 or totally rural 
 
Note. United States Department of Agriculture (2013).  Rural-urban continuum codes.  Retrieved 
from http://www.ers.usda.gov/data-products/rural-urban-continuum-codes/documentation.aspx.  
Table is in the public domain. Permission to reproduce was not required. 
 
 Survival rate: Survival rate is a term used when examining survival analysis, 
indicative of a certain percentage of people in a study who are alive for a given period of 
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time after diagnosis (National Cancer Institute, n.d.).  This study will express survival 
rate as the percent of adults diagnosed with GBM still alive after 5 years. 
 Tumor size: For the purpose of this study, a classification system developed by 
SEER will be used to determine GBM tumor size.  This system, known as the Extent of 
Disease, uses a 3-digit numerical code to describe tumor size (National Institute of 
Health, 2007).  Using the largest diameter of the tumor, the size of the tumor is coded 
(NCI, 1998).  These data are used by health care providers to determine the extent of a 
patient’s disease and prognosis of the particular cancer involved.  It is often referred to as 
collaborative staging.  Every type of neoplasm has its own collaborative stage for tumor 
size.  Table 3 is specific to brain tumors. 
Table 3 
 
Brain: Collaborative Stage for Tumor Size 
 
Code Description 
000 No mass or tumor found 
001-988 001 – 988 millimeters (mm). Exact size to nearest mm 
989 989 mm or larger 
990 Microscopic only and no size of given 
991 Tumor is “less than 1 centimeter (cm)” 
992 Tumor is “less than 2 cm” or “greater than 1 cm” or “between 1 cm and 2 cm” 
993 Tumor is “less than 3 cm” or “greater than 2 cm” or “between 2 cm and 3 cm” 
994 Tumor is “less than 4 cm” or “greater than 3 cm” or “between 3 cm and 4 cm” 
995 Tumor is “less than 5 cm” or “greater than 4 cm” or “between 4 cm and 5 cm” 
999 Size not known due to lack of documentation 
 
Note. Adamo, M., Dickie, L., & Ruhl, J. (May 2014). 2014 SEER Program Coding and Staging Manual. 
National Cancer Institute, Bethesda, MD: United States Department of Health and Human Services. Table 
is in the public domain.  Permission to reproduce was not required.  
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Assumptions 
In this study, I focused on differences in GBM tumor size at diagnosis, treatment 
options, and survival rates in urban and rural GBM patients across SEER registries.  The 
following assumptions are important in understanding the context of this particular study.  
First, the scope of this study is limited to an examination of urban and rural GBM 
patients.  Second, a GBM tumor is a Grade 4 neoplasm, and by the time symptoms 
appear, it is considered to be in an advanced stage of development.  Third, rural 
populations differ from their urban counterparts.  Fourth, there are specific features of the 
rural environment that create obstacles to one’s ability to access healthcare like a lack of 
health insurance or financial resources to pay for needed healthcare services, lack of 
healthcare resources themselves, and/or the distance and travel time to healthcare 
resources.  Fifth, urban regions have a greater concentration of physicians, hospitals, 
specialty healthcare centers, and advanced diagnostic capabilities than rural regions.   
Scope and Delimitations 
Since this study is descriptive in nature only, one cannot draw conclusions of 
causation. Furthermore, this study focuses only on the subpopulation of adult patients 
diagnosed with GBM.  Consequently, there is an inherent sample bias that undermines 
the study’s external validity. 
Limitations 
First and foremost, this study is based exclusively on secondary data obtained 
from the SEER database representing 28% of the United States population (National 
Cancer Institute, n.d.).  This limits the generalizability of results to all populations.  To 
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minimize this limitation, descriptive statistics will be used to describe study results, and 
confounding variables will be controlled.  Second, confounding conditions of the study 
population pose a threat to internal validity (Graves, 2011).  Since GBMs are most 
common in the elderly who have complex health issues, survival could be affected by 
potential confounding conditions other than the GBM itself.  The SEER database reports 
only on cancer information and incidence.  It does not address lifestyle factors or causes 
of cancer.  Since this is a quantitative, retrospective cohort study, the use of descriptive 
statistics should minimize this particular limitation. Third, since the database will cover a 
23-year timeframe from 1988 to 2011, the loss of patients to follow-up could result in 
either an overestimate or underestimate of study results.  Loss of patients from SEER 
registries are primarily due to patient interest, name and address changes, and/or death.  
With the GBM population, survival is usually 12 to 15 months or less from time of 
diagnosis.  Since SEER does follow all patients until death, and the survival rate for 
GBM patients is poor, the likelihood of losing patients to follow-up should be minimal. 
Fourth, this particular study is based exclusively on the SEER definitions of RUCCS, 
which ultimately affect the generalizability of results.  There is no single, universally 
accepted definition of rural.  However, counties are the most commonly used geographic 
component of rural definitions.  The advantages of using “counties” to describe urban 
from rural areas are that they are simple to understand and their boundaries are very 
stable over time. Additionally, many national health data sets use counties as a core 
geographic unit. Finally, RUCCs data are provided as a numeric continuum, and as such, 
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must be treated as ordinal data since there is no equal distance between codes (Hall, 
Kaufman, & Ricketts, 2007). 
Significance of the Study 
With the recent advances in genetics and genomes, a plethora of research has 
focused on the identification of genes specific to GBM.  In contrast, very little research 
has been done to study brain cancer from a geographical perspective.  This project is 
unique in that examining patients diagnosed with GBM from an urban-rural perspective 
has never been done before, highlighting a significant gap in the literature.  Specifically, I 
will examine the association between exposure to rural versus urban locations on tumor 
size at diagnosis, the number of patients that experienced surgical resection, the number 
of patients who experienced adjuvant therapies of radiation treatment and chemotherapy, 
and survival of GBM patients.  The independent variables are region, dichotomized to 
urban or rural areas, race, age, sex, educational level, and family income.  The dependent 
variables are tumor size, surgical resection, adjuvant therapies of radiation treatment and 
chemotherapy, and survival rates.  GBMs are a significant public health issue.  
Identification of the associations of these variables may provide insight into earlier 
detection resulting in improved survival rates GBM patients.  This study can significantly 
impact social change by identifying geographical predictive variables associated with 
health outcomes of GBM patients, thereby leading to earlier detection and improved 
survival rates of individuals and populations. 
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Summary and Transition 
Cancer is a worldwide health issue.  GBM is a malignant brain tumor in adults, 
distinctively characterized by its aggressiveness to spread rapidly, invade deeply and 
infiltrate healthy brain tissue, and result in death 12 to 15 months after initial diagnosis.  
Delays in detection and treatment contribute to its dismal prognosis.  In this study, I 
examined the relationship between GBM patients and the geographic regions where they 
live and work.  I also explored the variables of tumor size, the treatment modality of 
surgical resection, adjuvant therapies of radiation treatment and chemotherapy, and 
survival of GBM patients in urban and rural regions.  Using the SEER database covering 
1988 through 2011, descriptive and multivariable analyses of data provided an 
examination into the complex phenomena of GBM in rural and urban populations.  
Analysis of this type can provide valuable information to those responsible for the 
creation of healthcare policies and the allocation of healthcare resources. 
Chapter 2 includes a review of the existing literature on GBM in adult 
populations, the theoretical framework associated with this study, and a discussion of 
healthcare access.  Chapter 2 also includes a discussion of geographic variations of 
healthcare in general, including rural and urban differences in GBM incidence and 
survival, provides an overview of brain tumors and the epidemiology of GBM, and 
identifies the gap in the literature with respect to geographic differences specific to the 
GBM population.  I conclude Chapter 2 with an explanation for ongoing GBM research.
22 
 
 
Chapter 2: Literature Review 
In this chapter, I provide a systematic review of the literature pertinent to this 
study.  I first explore the theoretical framework used for this study.  Additionally, I 
discuss the geographic variations of GBM in the United States. I then explore the clinical 
attributes of GBM including its definition, symptomatology, detection, prognostic 
characteristics, diagnosis, and treatment options followed by the epidemiological 
characteristics of GBM from a person, place, and time perspective based on the most 
current literature.  Major studies on GBM will be reviewed and summarized.  
Specifically, this discussion compares and contrasts urban and rural regions of the United 
States by examining tumor size at diagnosis, the number of patients that experienced 
surgical resection, the number of patients who experienced the adjuvant therapies of 
radiation treatment and chemotherapy, and survival rate.  Finally, an analysis of this 
literature review highlights a knowledge gap regarding urban and rural variations in 
tumor size, the treatment modality of surgical resection, adjuvant therapies of radiation 
treatment and chemotherapy, and survival rate in GBM patients.   
The literature review included an evaluation of the following databases available 
through the internet: the Academic Search Premier database of Walden University, 
MEDLINE, PUBMED, Science Direct, and ProQuest for dissertations. This approach 
generated hundreds of peer reviewed articles on GBM.  Peer-reviewed journal articles 
were included if they were published in English and without date limitations.  
Publications referenced in peer-reviewed articles specific to GBM were also included in 
the search strategy.  Key terms used in the search strategy included glioblastoma 
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multiforme, GBM, gliomas, and brain tumors combined with the following terms: 
geography, geographic variation, regional, regional variation, urban-rural, 
metropolitan-nonmetropolitan, brain tumors, primary brain tumors, gliomas, GBM 
epidemiology, prognosis, and SEER. 
Theoretical Framework 
This study used Andersen’s behavioral model of health services use (1995) as its 
theoretical framework.  This theoretical framework has been used in studies that 
examined access to healthcare, determined the quality of care delivered, and evaluated 
associated outcomes (Blustein & Weitzman, 1995; Fryer et al., 1999; Love & Lindquist, 
1995).  The framework for this study is based on the hypothesis that late access to general 
and cancer diagnostic services for patients experiencing GBM may potentially lead to 
increased tumor size, decreased treatment options, and decreased survival rates.   
Concerned with inequalities to medical care access, Andersen initiated studies on 
the concepts of access in 1968.  The behavioral model (Figure 2) focused on the family 
unit, how and why the family used health services, and access to medical care.   
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Figure 2.  The initial behavioral model (1960s).Andersen, R.M. (1995).  Revisiting the 
behavioral model and access to medical care: Does it matter?  Journal of Health and 
Social Behavior, 36, 1-10.  Reprinted with permission.  
 
Andersen’s (1995) model infers that an individual’s use of healthcare relies on 
one’s general predisposition concerning health services, issues that enable or block 
utilization of services, and one’s inherent need to seek health care.  Andersen and Aday 
(1974) further examined concepts of medical care access and developed a more cohesive 
theoretical framework showing initial measures of access to medical care (Figure 3).  
Andersen (1995) noted that the purpose of the initial measures of access was to identify 
situations that either enhance access to healthcare services or obstruct access to the same 
services. 
25 
 
 
 
Figure 3.  Initial measures of access of the health behavior model. Andersen, R.M. 
(1995).  Revisiting the behavioral model and access to medical care: Does it matter?  
Journal of Social Behavior, 36, 1-10.  Reprinted with permission. 
 
 By 1995, Andersen revised the original focus on access to a behavioral approach 
of health services use with the assertion that using health services should either maintain 
the health status of the population served or improve the population’s health status, both 
perceived by the population and/or evaluated by health professionals (Andersen, 
Davidson, & Ganz, 1994; Figure 7).  The model also recognizes the importance of how 
the external environment contributes to the use of health services.  Andersen (1995) noted 
that this final model shows the many influences of health services use and eventually 
health status.  This model provides feedback loops indicated by the arrows in the diagram 
that highlight the interrelatedness of all the factors that make up this model (Andersen, 
1995).   
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Figure 4.  An emerging model identified as Phase 4 of the health behavior model. 
Andersen, R.M. (1995).  Revisiting the behavioral model and access to medical care: 
Does it matter?  Journal of Social Behavior, 36, 1-10.  Reprinted with permission. 
 
The following concepts, identified by Aday and Andersen (1974), are critical to 
understanding the behavioral model: 
1. Health policy: Viewed as a starting point for understanding access to health care.  
Aday and Andersen (1974) acknowledged that those professionals involved with 
health planning and creating policy are concerned with effecting health policy in 
order to improve access to medical care.  
2. Health care delivery system: Comprised of resources and organization. 
a. Resources are defined as the workforce and funds devoted to health care 
including health care personnel, physical structures where health care is 
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delivered, and equipment and supplies used to provide health care 
services.  
b. Organization refers to what and how the system handles its resources.  The 
components of organization are entry and structure. 
i. Entry is the process of entering the healthcare system, otherwise 
known as access. 
ii. Structure refers to the characteristics of the system that determines 
the needs of the patient at the time of service. 
3. Characteristics of the population at risk: Viewed as the individual’s determinants 
of health care utilization. 
a. Predisposing factors are the sociocultural aspects of individuals that exist 
like age, gender, educational level, occupation, race, and ethnicity 
(Andersen, 1995).  
b. Enabling factors involve resources that promote the use of health care 
such as adequate income and insurance coverage (Andersen, 1995).  
Additionally, the location of healthcare services is significant for people’s 
ability to access health services (Aday & Andersen, 1974).  
c. Need factors are the reasons why health care is sought (illness, accident) 
(Andersen, 1995).   
4. Utilization of health care services: Those characteristics that identify what 
happens to the individual upon entry (or nonentry) into the system (Aday & 
Andersen, 1974; Andersen, 1995). 
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5. Consumer satisfaction: Measures users’ satisfaction with the quantity or quality of 
care actually received. This dimension of access is measured by subjective 
perceptions in relation to convenience, coordination, cost, courtesy, and 
information provided.   
Andersen’s (1995) model is most meaningful in considering access from the 
perspective of whether those people who need care actually get into the system.  A more 
precise model for measuring or quantifying access will improve awareness of the 
availability and utilization of health services by certain subgroups within the population.  
Graves (2011) noted that understanding the specific needs, predisposing factors, and 
enabling resources of people living in particular regions can ultimately effect alterations 
in health outcomes.  The assessment of tumor size, treatment options, and survival rates 
for GBM patients and the relationship to location of health services (urban versus rural 
areas) can potentially improve survival rates.  Therefore, the adaptation of Andersen’s 
HBM model to the GBM population in urban versus rural areas is presented in this study. 
Healthcare Access 
Aday and Andersen (1974) defined access as the ability to utilize healthcare 
services whenever and wherever the need arises.  Alternatively, potential access refers to 
having the resources that promote the use of healthcare services, otherwise known as 
enabling resources (Andersen, 1995; Graves, 2011).  Therefore, if one possesses more 
enabling resources, chances are that the healthcare system will be used.  Alternatively, a 
shortage or absence of enabling resources could ultimately result in one’s decreased 
ability to enter the health care system.  A 1973 report by the United States Department of 
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Agriculture examined the provision of healthcare services in rural versus urban regions 
and concluded that populations living in rural regions do not have equal access to 
healthcare compared to their urban counterparts.  The report goes on to say that rural 
regions are deficient in medical personnel and healthcare facilities, and populations in 
rural regions do not have the economic capabilities to afford the costs of illness (Lepine 
& Le Nestour, 2012). 
The concept of access describes the association or connection between the basic 
need for healthcare and the actual delivery of healthcare.  From a conceptual perspective, 
access is further divided into the following categories: acceptability, accessibility, 
accommodation, affordability, and availability.  Accessibility is subdivided into socio-
organizational and geographical aspects such as distance transportation and travel time to 
and from health care services (Aday & Andersen, 1974).  However, most measures of 
access highlight the actual location of healthcare services and how the needs of the 
associated population in question are being met (Graves, 2009).   
In 1971, Hart described the state of heath care services in Great Britain as an 
imbalance between need and provision.  Hart observed that the lower social classes in 
Great Britain had higher morbidity and mortality rates than those in higher social classes.  
He proposed the Inverse Care Law where “the availability of quality medical care varies 
inversely with the need for care in the particular population served” (Hart, 1971, p. 405).  
Despite present-day advances in healthcare, the inverse relationship of need and 
provision persists.  According to Murray and Lopez (1997), this inverse relationship is 
most evident in developing countries.  Gatrell (2002) noted that in 1990, developing 
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countries had 90% of the disease burden but only 10% of global health expenditures.  
Current literature on developed countries has suggested that this inverse relationship 
continues to exist in Britain’s healthcare system today (Lovett, Haynes, Sunnenberg, & 
Gale, 2002).   
Access and Health Outcomes 
Aday and Andersen (1974) identified health outcomes as the end products of 
access and include the indicators of health status, satisfaction, and quality of life.  Past 
research has demonstrated differences in health outcomes by specific subpopulations who 
faced barriers to accessing high quality health care (Black, Langham, & Petticrew, 1995; 
Blustein & Weitzman, 1995; Bullen, 1996; Goodman et al., 1997; Sempos, Cooper, 
Kovar, & McMillen, 1988; Weitzman et al., 1997).  Differences in health outcomes might 
be how frequently a disease affects a group or how often the disease results in death. 
These differences in health outcomes are known as healthcare disparities, and when 
disparities are identified, it is assumed that inequalities in healthcare could exist (Agency 
for Healthcare Research and Quality, 2013).  Inequalities result in underserved, at-risk 
populations like minority groups, the elderly, women, children, the elderly, low-income 
populations, rural residents, and special needs populations (Agency for Healthcare 
Research Quality, 2004).      
Access and Rural Health 
There are numerous definitions of rural regions or rurality that have been used by 
various federal agencies of the United States.  For this particular study, the definition 
developed by the United States Department of Agriculture (USDA) will be examined.  
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The Economic Research Service (ERS), a division within the USDA created a model 
known as RUCCs to describe the distinctions between rural regions and urban regions 
(USDA, 2002).  The RUCCS model is based on metropolitan (urban) versus 
nonmetropolitan (rural) regions of the United States.  In Table 4, the model starts with 
metro or urban regions classified into three separate categories by the size of the 
population.  Conversely, nonmetropolitan regions are classified by how close they are to 
urban regions, often referred to as adjacency.  In Table 4, Codes 1 through 3 refer to 
urban counties by population size, while Codes 4 through 9 identify rural counties by 
their proximity or adjacency to an urban area with a given population size (USDA, 2002).   
Table 4 
 
Urban and Rural Classifications 
 
 
Note. Economic Research Service (2013).  2013 rural-urban continuum codes.  Retrieved 
from http://www.ers.usda.gov/data-products/rural-urban-continuum-
codes/documentation.aspx.Table is in the public domain.  Permission to reproduce is not 
required. 
 
Metropolitan Counties Definition 
Code  
1 Metro area with 1 million or more people 
2 Metro area with 250,000 to 1 million people 
3 Metro area with fewer than 250,000 people 
Nonmetropolitan Counties   
Code  
4 Adjacent to metro area, 20,000 or more people 
5 Nonadjacent to metro area, 20,000 or more people 
6 Adjacent to metro area, 2,500 to 19,999 people 
7 Nonadjacent to metro area, 2,500 to 19,999 people 
8 
9 
Adjacent to metro area, < 2,500 people or totally rural 
Non adjacent to metro area, < 2,500 or totally rural 
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Geographic Perspectives: Urban Versus Rural Regions 
From a public health perspective, there has always been significant interest in the 
health of populations from a geographic vantage point of where people reside.  Research 
has demonstrated the important connection between place of residence and health 
(Eberhardt & Pamuk, 2004; Tunstall, Shaw, & Darling, 2004).  Specifically, there is a 
dearth of research on health care and health outcomes in rural and urban areas.  This 
research originally focused on access, cost, and the distribution of healthcare resources 
like medical providers, clinics, and hospitals (Aday & Andersen, 1974; Hartley, 2004; 
Vlahov, Galea, & Freudenberg, 2005).  Current research in the rural-urban arena is on the 
determinants of health and the resultant similarities and differences on health behaviors 
and outcomes (Meade & Emch, 2010). 
At least half of the world’s population lives in urban regions (United Nations 
Population Fund, 2011).  From a social and environmental perspective, urban life is quite 
different from rural life.  Urban life is distinguished by the following characteristics: 
dense and diverse populations, complex systems, extensive social and political networks, 
increased growth of slums, a dearth of hazardous waste sites, increased indoor and 
outdoor pollution, noise exposure, and inadequate, over-crowded living conditions 
(Lauber & Tidball, 2014; Vlahov et al., 2005).   
Alternatively, rural regions show populations that are more spread out across 
wider farmland type areas and characterized by a lower socioeconomic status, earlier 
mortality before 75 years of age (Eberhardt & Pamuk, 2004), along with higher mortality 
rates from accidents and suicide (Eberhardt et al., 2001).  Rural populations tend to 
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smoke excessively (Monroe, Ricketts, & Savitz, 1992), and have higher mortality rates 
from chronic obstructive pulmonary disease (Eberhardt et al, 2001).  Research has shown 
mixed results for cancer mortality rates across rural regions of the United States.  For 
example, Yabroff et al. (2005) demonstrated higher mortality rates due to cervical cancer 
in women living in the central California valley, southern portions of the United States, 
and rural Appalachia, compared to their urban counterparts.  A 2011 study examined the 
mortality rates for all cancers in the United States, and found that rural residents had 
higher cancer mortality of the prostate, cervix, lung, and colon (Singh et al., 2011).  
Research has also demonstrated that populations living in rural regions travel longer 
distances and to urban areas to obtain needed medical care (Chan, Hart, & Goodman, 
2006).  Ricketts (2000) specifically pointed out that rural areas are constantly suffering 
from physician shortages since only 11% of all physicians practicing in the United States 
are based in rural areas.  Reschovsky and Staiti (2005) determined that the physician 
shortage is far greater among specialists in rural areas.  Since rural patients have a lower 
socioeconomic status, they are less likely to have insurance which discourage them from 
seeking needed medical care.  When illness becomes so great and patients have to obtain 
needed care, they have to wait longer for appointments due to physician shortage, have to 
travel far greater distances to see specialists, and are usually in advanced stages of 
disease progression. 
Brain Tumors: General Overview 
 The brain and spinal cord, taken together are known as the Central Nervous 
System (CNS; Buckner et al., 2007).  The CNS regulates all the vital functions of the 
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body such as all body movements, speech, and thoughts (Buckner et al., 2007).  When a 
brain tumor occurs in the CNS, it can significantly affect one’s thought processes, 
communication abilities, and movement capabilities (American Society of Clinical 
Oncology, 2012).  Brain tumors occur when normal brain cells change and grow 
uncontrollably ultimately forming a collection of abnormal cells (National Cancer 
Institute, 2009).  Brain tumors are classified as primary or secondary.  Primary brain 
tumors start in the brain, and rarely metastasize to other parts of the human body 
(National Cancer Institute, 2009).  Secondary brain tumors, otherwise known as 
metastatic brain tumors, occur when cancer cells from another part of the body, such as 
the lung, breast, or colon, spread or metastasize to the brain via the bloodstream (National 
Cancer Institute, 2009).  The distinction between primary and secondary brain tumors is 
clinically important since treatment modalities are quite different.  
 There are over 100 different types of primary brain tumors that are identified and 
categorized by microscopic examination otherwise known as histopathologic 
classification.  Approximately 50% of these brain tumors come from a specific cell in the 
brain known as a glial cell (Jellinger, 1978).  First identified by the German pathologist, 
Rudolf Virchow, in 1860, these primary brain tumors are known as gliomas, and Virchow 
used terms like teleangiectatic and hemorrhagic to further describe these tumors 
(Jellinger, 1978).  Gliomas originate from primitive cells known as astrocytes, and brain 
tumors that originate from astrocytes are called astrocytomas (Jellinger, 1978).  
Astrocytomas are given a grade from I to IV for how much the tumor looks like normal 
brain tissue and how quickly the cells grow often referred to as aggressiveness (American 
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Society of Clinical Oncology, 2014).  This grading system, specific to brain tumors, is 
primarily used to determine a patient’s prognosis.  Lower grades are less abnormal and 
slow-growing while higher grades are more abnormal and fast-growing.  The World 
Health Organization (WHO) classifies astrocytomas in the following ways: 
• Grade I (Pilocytic Astrocytoma):  A brain tumor that grows slowly, does not 
metastasize to other areas of the CNS, the least malignant, and accounts for 2% of 
all brain tumors (American Society of Clinical Oncology, 2014). 
• Grade II (Low-grade Astrocytoma):  A relatively slow-growing brain tumor that 
may or may not metastasize to other parts of the CNS, tends to recur post-
treatment, and accounts for 3% of all brain tumors (American Society of Clinical 
Oncology, 2014). 
• Grade III (Anaplastic Astrocytoma):  A malignant brain tumor that grows quickly, 
invades nearby brain tissue, and accounts for less than 5% of all brain tumors 
(American Society of Clinical Oncology, 2014; Louis et al., 2007). 
• Grade IV (GBM):  An extremely aggressive and highly malignant brain tumor 
that rapidly invades normal brain tissue, characterized by areas of necrosis (dead 
cells) in the center of the tumor when viewed under a microscope, and accounts 
for 25% of all primary brain tumors (American Society of Clinical Oncology, 
2014; Louis et al., 2007; Wang et al., 2011). 
Glioblastoma Multiforme: Definition and Description 
 The term glioblastoma multiforme was first used in 1925 by Globus and Straus as 
a replacement for the category known as spongioblastoma multiforme.  On microscopic 
36 
 
 
examination, a GBM is typically recognized as having large areas of necrosis and 
microvascular proliferation (the formation of new blood vessels from preexisting blood 
vessels), a hallmark sign in aggressive cancers (Shabason, Tofilon, & Camphausen, 
2011).  In general, GBM tumors have the appearance of malignant cells surrounding 
areas of necrosis and hemorrhage (Louis, Holland, & Cairncross, 2001; Shabason et al., 
2011).  Due to its hemorrhagic, proliferative, and aggressive qualities, the median 
survival time for a newly diagnosed patient is approximately one year (Aldape, Okcu, 
Bondy, & Wrensch, 2003). 
Epidemiology of Glioblastoma Multiforme: Person, Place, and Time 
In the United States, primary malignant brain tumors are rare, accounting for 
approximately 2% of all adult cancers (American Cancer Society, 2012a; Patel et al., 
2014).  Despite their rarity, brain cancer incidence has increased over the last 30 years 
while survival rates remain abysmally poor (Deorah, Lynch, Sibenaller, & Ryken, 2006).  
From 1973 to 2001, over 38,000 cases of malignant brain tumor were reported to the 
SEER 9 database, and almost 17,000 cases were diagnosed as GBM (Deorah et al., 
2006).  GBM is the most commonly-occurring brain neoplasm in adults. .The following 
epidemiological facts are known about GBM: 
• 1.6 times more common in men than women (Ivan, Tate, & Clarke, 2012).  
• Two to three times higher among Caucasians than blacks, American Indians and 
Alaskan natives, and Asian-Pacific Islanders race groups (Ohgaki & Kleihues, 
2005).   
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• Occurs more frequently in older adults (Dolecek, Propp, Stroup, & Kruchko, 
2012), and increase with age with primary occurrence in adults from 45-70 years 
old although the highest rates occur in the 75 to 84 year-old age group (Ivan, Tate, 
& Clarke, 2012; National Cancer Institute, 2012). 
• In most elderly patients, GBMs arise abruptly and grow quickly, impairing 
cognition and drastically reducing functional independence (Hutterer, 2009). 
Furthermore, GBM treatments in older people are less effective and more toxic 
than in younger people. 
As in the United States, GBM is the most common primary brain tumor worldwide, 
with an incidence of 2-3 new cases per 100,000 people per year (Central Brain Tumor 
Registry of the United States, 2012).  The relative survival estimates for patients 
diagnosed with GBM show less than 5% of patients surviving five years post-diagnosis 
(Central Brain Tumor Registry of the United States, 2012).  Aldape et al. (2003) noted 
that the median survival for patients newly diagnosed with GBM and undergoing typical 
treatment options is 12 months.  Despite the advent of modern-day diagnostic capabilities 
along with improved and enhanced treatment modalities, survival time has not 
significantly improved.  
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Figure 5.  Microscopic view of normal brain tissue and brain tissue with a GBM. 
Note. College of American Pathologists (2012). Brain tumor: Glioblastoma. 
http://www.cap.org/apps/docs/reference/myBiopsy/glioblastoma.html. Figure is in the 
public domain.  Permission to reproduce not required. 
 
 
Figure 6.  Magnetic resonance image (MRI) revealing a mass in the brain that was later 
shown to be a glioblastoma multiforme (indicated by arrow). 
Note. National Institutes of Health (2014).  Glioblastoma multiforme.  The Cancer 
Genome Atlas. Retrieved from 
http://cancergenome.nih.gov/cancersselected/glioblastomamultiforme.  Figure is in the 
public domain.  Permission to reproduce not required. 
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Treatment Modalities of GBM 
The management of GBM has progressively evolved over the last two decades 
with new technological advances that have led to improve diagnosis, site-specific 
radiation techniques, surgical procedures, and improved chemotherapies.  Yabroff, 
Harlan, Zeruto, Abrams, and Mann (2012) note that GBM treatment is limited by its 
primary location (brain) and its infiltrating vascularity.  According to Ivan, Tate, and 
Clarke (2012), prior to 2005, the typical standard of care for newly diagnosed GBM 
patients was surgical removal of the tumor followed by radiation therapy (adjuvant 
radiotherapy).  Whether or not chemotherapy administration was beneficial in the 
treatment of GBM was not clear (Yabroff et al., 2012).  However, in 2005, a landmark 
study demonstrated that overall survival was prolonged if the patient had maximal 
surgical resection of the tumor followed by concomitant therapies of radiation and 
administration of a chemotherapeutic agent identified as temozolomide (Stupp et al., 
2005).   
Prognostic Factors of GBM 
 The neuro-oncologic community universally agrees that a diagnosis of GBM is 
associated with a dismal prognosis (Stupp et al., 2005; Yuile, Dent, Cook, Biggs, & 
Little, 2006;Yabroff et al.,2012).  The prognosis of GBM remains poor despite ongoing 
therapeutic advancements.  Median survival from initial diagnosis is, at best, 
approximately one year.  Given the dismal prognosis, multimodal aggressive therapy 
consisting of surgical resection of the GBM tumor, radiation therapy, and chemotherapy 
administration is done in an attempt to prolong survival time.  In an attempt to understand 
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contributory factors associated with the development of GBM, studies have explored a 
multitude of exogenous factors such as smoking, diet, cell phone use, ionizing radiation, 
electromagnetic fields, immunological status, allergies, and viral infections just to name a 
few.  Unfortunately, there is no definitive evidence implicated in the development of 
GBM except for prolonged exposure to ionizing radiation. 
The difficulty in treating GBM is well recognized.  Researchers have sought to 
evaluate those factors that contribute to worsening survival times and/or prolonging 
survival times.  In order to optimize treatment modalities for individual patients, it is 
critical to evaluate prognostic factors that will enhance survival.  Data from the Glioma 
Outcomes Project demonstrated that patient age, functional status, and complete resection 
of the tumor were statistically significant prognostic indicators for patient survival (Laws 
et al., 2003).   
• Age is the most significant prognostic factor for survival.  It is noted that age 
younger than 60 years is a favorable prognostic factor (Mineo et al., 2007; 
Chandana, Movva, Arora, & Singh, 2008). 
• In an attempt to understand how well GBM patients are doing physically, medical 
providers will assess their ability to carry out everyday activities, or their 
functional capacity.  There are different kinds of functional tests that practitioners 
use to determine a patient’s level of functioning.  One of the most commonly used 
tests is identified as the Karnofsky Performance Scale (KPS) developed in 1949 
by Karnofsky and Burchenal.  A patient can score anywhere from 0 to 100, with 0 
representing death while 100 is considered normal with no evidence of disease.  A 
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score of 80 or greater is considered a good prognostic indicator for GBM patients 
(Stark, Stepper, & Medhorn, 2010). 
• Removal of the entire GBM tumor is impossible because of the hyper-vascularity 
and invasiveness of the tumor.  Therefore, surgeons strive to remove as much of 
the tumor as possible to decrease the tumor size, relieve pressure on the brain 
known as intracranial pressure (ICP), and prolong survival (Chandana et al., 
2008).  Hentschel and Lang (2004) noted that aggressive resection where more 
than 98 % of the GBM tumor is removed is associated with a statistically 
significant improved survival rate.  
• Epilepsy or seizures represent a significant prognostic factor because it leads to 
earlier diagnosis (Mineo et al., 2007; Chandana et al., 2008). However, there are 
many GBM patients who never experience seizures.   
• Patients who present with acute onset or significantly disturbing symptoms show 
improved survival when compared to patients who experience symptoms that are 
subtle or slower to evolve (Yulie et al., 2006). 
Summary 
This chapter included a review of the literature pertinent to this study.  I described 
Andersen’s Health Behavioral Model which serves as the theoretical framework used for 
this study.  Additionally, this chapter included a discussion of the geographic variations 
of GBM in the United States, the clinical attributes of GBM including its definition, 
symptomatology, detection, prognostic characteristics, diagnosis, and treatment options 
followed by the epidemiological characteristics of GBM from a person, place, and time 
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perspective based on the most current literature.  Major studies on GBM were reviewed 
and summarized.  Finally, analysis of this literature review highlighted a knowledge gap 
regarding urban and rural variances in tumor size, treatment options, and survival rate in 
GBM patients.   
 Almost 20 % of the population in the United States lives in a rural setting, are 
generally older, usually unemployed, experience greater poverty, tend to be in poor 
health, and are usually uninsured  (Hart et al., 2005).  Rural residents are challenged with 
barriers when trying to access health care services such as traveling longer distances to 
reach health care facilities, and have fewer doctors and hospitals than urban residents. By 
the time rural residents do access the healthcare system, their health issues may be more 
serious or far advanced.  This study will help fill the knowledge gap related to geographic 
variations in GBM tumor size, treatment options, and survival rate. Research that focuses 
on early detection of GBM, increasing GBM awareness, and geographic variation has 
received inadequate attention.  This study may help to fill the void in the current state of 
affairs related to GBM, and thereby lead to future research that will improve survival 
rates in this deadly disease. 
 In Chapter 3, I discuss the study methodology that used to address the primary 
research question: Are there differences in tumor size, treatment options, and survival 
rate between urban and rural GBM patients?  Chapter 3 describes the research design, 
setting, sample and eligibility criteria.  Additionally, Chapter 3 offers a thorough 
discussion of instrumentation and materials, data collection, and analysis.  Finally, 
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Chapter 3 closes with a discussion on maintaining quality assurance and confidentiality, 
and ensuring protection of human subjects. 
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Chapter 3: Research Method 
Introduction 
In this study, I focused on patients 20 years and older who have been diagnosed 
with GBM.  My purpose was to determine if differences in tumor size, treatment options, 
and survival rate occur in GBM patients living in urban versus rural regions of the United 
States.  This chapter delineated the research design, data setting, and sample.  A 
discussion of the research design section included the rationale for the design of the 
study.  The setting and sample section included a description of the study’s sample 
population and criteria for inclusion. The instrumentation and materials section included 
a discussion of the SEER database and cancer registries.  The data collection and analysis 
section addressed the research questions and study variables.  The final section provided 
a discussion of quality assurance, confidentiality of study subjects, and protecting human 
research participants. 
Research Design and Approach 
 This retrospective study explored the differences in GBM tumor size, treatment 
options, and survival rate in urban versus rural patients.  The independent variables were 
urban (metropolitan) and rural (nonmetropolitan) areas.  The dependent variables were 
tumor size at diagnosis, treatment options (surgical resection and adjuvant therapies of 
radiation treatment and chemotherapy), and survival rate.  Using secondary data sets 
available through the SEER program, this was a quantitative, retrospective cohort study.  
The SEER Program is a division of the National Cancer Institutes (NCI) involved in the 
collection of cancer data across the United States.  Cancer data is collected by specially-
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trained personnel from 18 cancer registries representing 28% of the United States 
population (SEER, 2013).  The SEER registries consistently collect the following types 
of data: patient information, type of cancer, primary location of the cancer or tumor, 
tumor size, microscopic composition of the tumor, stage and grade of the tumor, 
treatment options, and survival data (SEER, 2013).  Once the data are collected, the data 
are then analyzed for cancer trends in the United States, including cancer incidence for 
specific cancers, population characteristics, treatment options, and survival and mortality 
data. 
 The primary benefits of a retrospective cohort design are that it is less expensive, 
easier to conduct, less prone to bias, and optimal for multiple outcomes analysis (Mann, 
2003).  Additionally, since the SEER database is linked to census data, researchers can 
examine disease patterns across numerous demographic and socioeconomic variables 
(SEER, 2013).  A major disadvantage of a retrospective cohort design involves collection 
of data prior to the study. For instance, failure to adhere to data standardization 
procedures may lead to incomplete or erroneous entries.  Another disadvantage of 
retrospective cohort studies is the inability to control for confounding variables (Mann, 
2003).  Finally, retrospective cohort studies may be prone to bias given the manner in 
which study subjects are selected and the potential for subjects to drop out of the study. 
Setting and Sample 
 Adult patients 20 years of age and older diagnosed with GBM served as the study 
population.  Data were collected and analyzed retrospectively using the most recent 
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SEER database covering the years 1973 through 2011.  For the purposes of this particular 
study, data were collected on GBM patients diagnosed from 1988 to 2011. 
Eligibility Criteria 
 The sample consisted of subjects with the following eligibility characteristics: (a) 
adults diagnosed with GBM, (b) age at diagnosis: all ages, (c) place of residence: urban 
(metropolitan) or rural (nonmetropolitan), (d) year of diagnosis: 1988 to 2011 inclusive, 
(e) race and ethnicity: all races and all ethnicities reported, (f) tumor size, (g) surgical 
resection (yes/no), (h) adjuvant therapies: radiation treatment (yes/no) and chemotherapy 
(yes/no),  and (i) survival time: 5 years after diagnosis.  The SEER database specifically 
classifies tumors by a collaborative staging code most commonly referred to as a CS 
code, and used to identify the part of the body where the tumor is found.  CS codes 
specific to GBM tumors corresponded to the particular lobe or area in the brain where the 
tumor was located. The CS codes for GBM tumors included C70.0 and C71.0-71.9. See 
Table 5 for location of brain tumors. 
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Table 5 
Brain/Cerebral Meninges 
CS code  Location 
C70.0 Cerebral meninges 
C71.0 Cerebrum 
C71.1 Frontal lobe 
C71.2 Temporal lobe 
C71.3 Parietal lobe 
C71.4 Occipital lobe 
C71.5 Ventricle, NOS* 
C71.6 Cerebellum, NOS* 
C71.7 Brain stem 
C71.8 Overlapping lesion of brain 
C71.9 Brain, NOS* (not otherwise specified) 
 
Note. Beahrs, O. H., Henson, D. E., Hutter, R. V. P., & Kennedy, B. J.(1992).  Manual for staging of 
cancer (4th ed.). Philadelphia, PA: J. B. Lippincott Company.    
 
Power Analysis 
 The power of a statistical test allows the researcher to decide the size of the 
sample needed to produce accurate and reliable results.  For this study, statistical power 
was calculated using a priori power analyses conducted using *G Power.  An a priori 
analysis was done to ascertain the required sample size that will achieve a given 
statistical power.  More specifically, the statistical power of a test detected that a 
phenomenon does in fact exist (Cohen, 1988; High, 2000).  
 For this study, the expectation was that the null hypothesis would be rejected for 
all research questions noted in the following: 
• Research Question 1: There is no significant difference in GBM tumor size 
between urban and rural patients. 
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• Research Question 2: There is no significant difference in the treatment option of 
surgical resection. 
• Research Question 3: There is no significant difference in the adjuvant therapies 
of radiation treatment and/or chemotherapy between urban and rural patients. 
• Research Question 4: There is no significant difference in GBM survival rates 
between urban and rural patients. 
• Research Question 5: There is no significant difference in GBM survival rates 
controlling for region, race, age, sex, educational, and family income in the study 
population of GBM cases. 
 Using G*Power v3.1.0 to determine the sample size, the test family of t tests were 
used. A calculation estimating the effect size was determined to be 0.32, or medium 
effect, and a power of 0.80 was selected.  Power analysis was done by entering the 
proportions for the null hypotheses (rural patients diagnosed with GBM will not present 
with larger tumor, limited treatment options, or have poorer survival) against proportions 
expected to be seen.  The G*Power Analysis calculator, developed by Faul, Erdfelder, 
Lang, and Buchner (2007) was set at the test family of t tests using the Mann-Whitney U 
test , the a priori total sample size was calculated at 256 (equal sample size in urban and 
rural groups).  Table 6 shows the G*Power Analysis Calculator. 
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Table 6 
 
G*Power Analysis Calculator (a priori) Independent Samples t Test Using the Mann-
Whitney U test  
 
Input Calculation 
Effect size w 0.32 
α err prob 0.5 
Power (1-β err prob) 0.80 
Allocation ratio N2/N1 1 
Input Calculation 
Noncentrality parameter λ 2.5016449 
Critical t 1.6511624 
Sample size group 1 128 
Sample size group 2 128 
Df 242.462 
Total sample size 256 
Actual power 0.8022824 
 
Note. To calculate the sample size for the Kaplan Meier and Cox Proportional Hazard 
Ratio, the MedCalc version 12.7.7 (Medcalc Software, 2013) was used.  The a priori 
sample size was calculated at 196 (equal sample size in urban and rural groups).  
 
Table 7 
 
Survival Analysis (logrank test): MedCalc (a priori): Compute Required Sample Size 
 
Options 
Type I error (alpha, significance)           0.05 
Type II error (Beta, 1-Power)           0.20 
 
Data 
Survival rate Group 1 0.6 
Survival rate Group 2 0.4 
Ratio of Sample Sizes in Group1/Group 2 1 
 
Result 
Number of cases required in Group 1 98 
Number of cases required in Group 2 98 
Total sample size (both groups together) 196 
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Data Collection and Analysis 
 The SEER Program provided a cancer database considered the preeminent source 
of cancer-specific and population statistics for the United States (SEER, 2013).  In 
addition to cancer-specific data, the SEER database captured population-based data like 
gender, race/ethnicity, age, date of original diagnosis, the geographic location of 
residence, patient-specific treatments, tumor stage and size, and patient survival data 
(SEER, 2013).  The advantages of using the SEER database included the following: (a) It 
is a relatively inexpensive way to obtain cancer-specific data; (b) its validity and 
reliability has been established; and (c) its comprehensiveness lends itself to obtaining a 
large sample size with increased power.  Data were manually extracted from the SEER 
database using SPSS (IBM Statistics Grad Pack Version 20). SPSS has the capability of 
handling sizeable datasets and the ability to perform data analysis employing an 
assortment of statistical tests.  
 This retrospective cohort study used secondary data obtained from the 1973-2011 
SEER database to examine the relationship between GBM cases in urban and rural areas, 
tumor size, functional status, and survival.  The data were publically available and readily 
accessible by signing a SEER Research Data Agreement (SEER, 2013).  This agreement 
stressed the importance of protecting the identities of cancer patients covered in the 
Protection of Human Subjects.  Data can be accessed via the Internet or on a DVD.  For 
this study, a request was made to have access to the data and SEER*Stat software via the 
Internet.  A personalized SEER Research Data Agreement was generated and signed, and 
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permission to access the data was granted (refer to Appendix A).  After permission was 
granted, a confidential and unique user name and password were assigned by SEER.  
 All GBM cases noted earlier were assigned to regions and dichotomized to urban 
and rural counties based on location of residence when diagnosed.  To further understand 
the regional variations, the study evaluated tumor size at diagnosis, the treatment option 
of surgical resection, adjuvant therapies of radiation treatment and chemotherapy, and 
survival rate.  Five research questions were evaluated:  
• Research Question 1: When comparing urban and rural patients with GBM, is 
there a significant difference in GBM tumor size at diagnosis? 
• Research Question 2: When comparing urban and rural patients with GBM, is 
there a significant difference in the number of GBM patients who experience 
surgical resection? 
• Research Question 3: When comparing urban and rural patients with GBM, is 
there a significant difference in the number of GBM patients who experience 
adjuvant therapies of radiation treatment and chemotherapy? 
• Research Question 4: When comparing urban and rural patients with GBM, is 
there a significant difference in GBM survival rates? 
• Research Question 5: In the study population of GBM patients, is there a 
significant difference in survival rates when controlling for region, race, age, sex, 
educational level, and median family income? 
Inclusion criteria included all GBM cases diagnosed in adults 20 years and older reported 
to SEER between 1988 and 2011.  Data on stage at diagnosis have been reported since 
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1975.  However, tumor size has only been reported since 1988 (Farrow, Samet, & Hunt, 
1996). Consequently, the SEER data were scrutinized for all GBM cases diagnosed from 
1988 through 2010 inclusive of data on tumor size.  
Independent Variable 
 The independent variable for this study is identified as region, apportioned to 
urban and rural counties.  In the SEER database, two other terms describe urban and 
rural: Metropolitan was used interchangeably with urban, and nonmetropolitan was used 
interchangeably with rural.  The independent variable of region was presumed to 
influence the dependent variables noted below.  The geographic features of urban and 
rural areas may be critical in accessing healthcare resources, early screening and 
detection, and providing basic preventive health services (Klein, 2010).  Rural 
populations have poorer access to healthcare facilities and resources that may affect not 
only access to healthcare in general but also access to preventive cancer screening and 
specialized health services.  Consequently, rural residents will not seek care at the time of 
need, and when care is finally sought, rural patients are found in advanced disease stages 
than their urban counterparts (Eberhardt et al., 2002). Complicating this scenario is the 
fact that rural residents face longer distances and travel times to medical facilities 
including cancer centers, treatment facilities, and specialized providers (Coughlin et al., 
2002).  
Dependent Variables 
 This study addresses four dependent variables: tumor size, surgical resection, 
adjuvant therapies of radiation treatment and chemotherapy, and survival rate. Past 
53 
 
 
research identified these variables as prognostic indicators for adults diagnosed with 
GBM. GBM is usually diagnosed at an advanced stage known as a Grade 4 tumor. Grade 
4 tumors are usually larger in size than early-stage tumors.  Larger tumors and advanced 
age at diagnosis are associated with a lower survival rate.  
Scales of Measurement 
 The level of measurement of the independent variable of region apportioned to 
urban and rural was nominal.  There were four dependent variables for this study: tumor 
size at initial diagnosis, surgical resection, adjuvant therapies of radiation treatment and 
chemotherapy, and survival rate. The level of measurement for tumor size was ordinal 
since the SEER database uses categories of tumor size ranges where tumor size is 
measured in centimeters.  Ordinal measurements assign observations into categories that 
can be put into rank order and do not quantify differences (Gerstman, 2008, p. 5).  Since 
rank orders do not quantify differences, conditions of normality and equal variance are 
absent.  Thus, a nonparametric statistic was be used.  Data analysis for the first research 
question used the Independent Samples t test or Mann-Whitney U test, depending on 
normality.  The level of measurement for surgical resection as reflected by whether or not 
the patient experienced surgical resection was nominal, and correlated to a simple 
classification of yes versus no.  Data analysis for the second research question involving 
surgical resections was conducted using the Independent Samples t test or the Mann-
Whitney U test depending on sample size and normality.  The level of measurement for 
adjuvant therapies of radiation treatment and chemotherapy as reflected by whether or not 
the patient experienced radiation treatment (yes/no) and/or chemotherapy (yes/no) was 
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nominal, and correlated to a simple classification of yes versus no for each adjuvant 
therapy of radiation treatment and chemotherapy.  The fourth research question on 
survival rate used two statistical tests.  First, the Kaplan-Meier was used for univariate 
analysis.  Second, the Cox proportional hazards (regression analysis) was used for 
multivariate analysis of survival differences between groups (urban and rural).  The fifth 
research question involving survival rates used multiple regression modeling to determine 
the best predictive model based on the independent variables of region, gender, race, age, 
marital status, education, and family income in the study population of GBM cases 
(Klein, Ji, Rea, & Stoodt, 2011).  Table 8 shows the multiple regression modeling and 
associated independent variables. 
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Table 8 
 
Variables for Multiple Regression Modeling 
 
Variables Rural (n) Rural % Urban (n) Urban % Total 
Race      
  Black      
  White      
  Other      
  Unknown      
Marital status      
  Single      
  Married      
  Widowed      
  Divorced/Separated      
Education level      
  Low      
  Medium      
  High      
AGE      
  < 50      
  50-70       
  71-80      
  > 80      
Median family income      
  < $50,000      
  $51,000 - $64,000      
  > $65,000      
 
Instrumentation and Materials 
 The database used is the SEER Program of the National Cancer Institute (NCI) 
(SEER, 2013).  A plethora of data is collected from 18 cancer registries across the United 
States, as noted in the data collection and analysis section.  The registries noted in Table 
9 correspond to their geographic location: 
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Table 9 
 
SEER 18 Registries 
 
Alaska Native Tumor Registry 
Arizona Indians  
Cherokee Nation  
Connecticut 
Detroit 
Georgia Center for Cancer 
Greater Bay Area Cancer Registry 
Greater California 
Hawaii 
Iowa 
Kentucky 
Los Angeles 
Louisiana 
New Jersey 
New Mexico 
Seattle-Puget Sound 
Utah 
 
Note. SEER (n.d.). List of SEER registries.  Washington, D.C.: United States Department of Health and 
Human Services.  Retrieved from http://seer.cancer.gov/registries/list.html.  Information is in the public 
domain.  Permission to reproduce not required. 
 
 The above noted geographic regions represented 28% of the United States 
population, and accounted for a broad cross section of the population representing 
different ethnicities, cultures, and geography (National Cancer Institute, 2010).  While 
the entire United States was not represented in the SEER database, the coverage was 
broad enough to account for the many population groups living in the United States 
(SEER, 2010).  For the purposes of this study, all of these regions identified in the SEER 
database were used for data collection, and then categorized into urban and rural areas 
using RUCCs.  Figure 7 shows the location of SEER registries across the United States. 
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Figure 7.  Locations of SEER registries across the United States 
Note. SEER (n.d.).  About the SEER registries.  Washington, DC:  United States Department of Health and 
Human Services.  Retrieved from http://seer.cancer.gov/registries/. Figure is in the public domain. 
Permission to reproduce not required. 
 
 The 18 population-based registries fall under the auspices of the North American 
Association of Central Cancer Registries (NAACCR).  The NAACCR provides guidance 
in data collection to all registries as a way of maintaining the integrity, quality, and 
accuracy of collected data (National Cancer Institute, n.d.).  The NAACCR has a rigorous 
audit and quality control process to ensure the accuracy of collected data (National 
Cancer Institute, n.d.), and study results are ultimately used to improve documentation of 
data (National Cancer Institute, n.d.). 
 In addition to state and regional registries, the SEER Program interfaces with 
other federal and state agencies as well as nationally-recognized databases for research 
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purposes.  For example, the National Center for Health Statistics provides mortality 
statistics, and the Census Bureau provides population data for the calculation of cancer 
rates (National Cancer Institute, n.d.).  SEER also works with the Centers for Medicare 
and Medicaid Services (CMS) to collect data on cancer statistics in the elderly.  Finally, 
SEER has joined forces with the National Longitudinal Mortality Study (NLMS) to 
explore cancer incidence, tumor characteristics, and survival rates from a socioeconomic 
and demographic perspective.   
Quality Assurance 
 The SEER database is considered the model of excellence for data quality, and 
often referred to as the gold standard for data collection.  Quality improvement is critical 
to enhancing and continuously improving data quality.  Quality improvement activities 
include case-finding audits related to data collection procedures, reliability studies that 
test the skills of registry personnel, and reabstraction studies at central and hospital 
cancer registries to continuously improve the input of meaningful data.  To safeguard all 
study-related materials and maintain confidentiality, data were secured on a password-
protected laptop with anti-virus software and internal firewalls.  All study files were 
backed up daily, and saved on a password-protected flash memory card (thumb drive) 
maintained in a locked file cabinet. The researcher was the only person with access to the 
laptop, thumb drive, and key to the file cabinet.  
Protection of Human Subjects 
 This study used secondary data sets from the SEER database.  All data were de-
identified as noted in the Privacy Rule which evolved from the Health Insurance 
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Portability and Accountability Act (HIPAA) of 1996.  Additionally, the SEER registry 
program requires the researcher to sign a Limited Use Agreement in order to grant access 
to the data (Appendix A).  Finally, an application for study approval was submitted to the 
Institutional Review Board (IRB) of Walden University (IRB approval # 01-28-14-
0174231).  Data collection and analysis moved forward once final approval was received 
from the IRB. 
Dissemination of Findings 
 Dissemination of research findings is a critical component of any study.  Equally 
important is Walden University’s commitment to social change. Therefore, synthesis and 
dissemination of research findings for this study provides relevant and valid research 
evidence and implications for social change to colleagues, clinicians, and health policy 
makers.   
Summary 
 Chapter 3 provided the basic methodology of this quantitative retrospective cohort 
study.  The research design and approach provided the systematic plan to study GBM 
patients in urban and rural regions in relationship to tumor size, treatment options, and 
survival rate.  The sample population was identified, including a thorough description of 
the eligibility criteria.  The selected instrumentation and materials provided a 
comprehensive examination of the data sources associated with the SEER registries.  
Data collection and analysis provided the context for the established research questions, 
independent and dependent variables and their associated levels of measurement.  Quality 
assurance focused on confidentiality, and the protection of human subjects provided 
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context around the Privacy Rule which grew out of HIPAA, the limited-use data 
agreement required by SEER, and subsequent IRB approval through Walden University.  
The methodology for this study was used to determine if urban and rural GBM patients 
experience differences in tumor size at diagnosis, surgical resections, adjuvant therapies 
of radiation treatment and chemotherapy, and survival rates using the U.S. SEER 
database.  Study results are covered in Chapter 4. 
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Chapter 4: Results 
 The purpose of this retrospective, quantitative study was to ascertain if there are 
differences in tumor size, treatment options, and survival rates between rural and urban 
patients diagnosed with GBM.  Research Question 1: Was there a potential relationship 
of GBM tumor size in urban and rural patients?  Research Question 2: Was there a link 
between the treatment option of surgical resections in urban and rural patients?  Research 
Question 3:  Was there a relationship between treatment options of radiation therapy and 
chemotherapy in urban and rural patients?  Research Question 4: Were there differences 
in survival rates of urban and rural patients.  Research Question 5: Were there differences 
in survival rates of urban and rural patients when controlling for region, race, age, sex, 
educational level, and median family income?  The hypothesis under review is that rural 
patients diagnosed with GBM will present with larger tumor size, experience fewer 
treatment options of surgical resections, radiation therapy, and chemotherapy, and have 
poorer survival rates compared to urban patients diagnosed with GBM. 
I begin this chapter with a detailed description of data collection methods and any 
discrepancies from the outlined plan provided in Chapter 3.  Next, descriptive statistics 
are provided for every variable of the study population.  Finally, all statistical analyses 
specific to each research question are explained in detail. 
Data Collection 
This retrospective cohort study used secondary data obtained from the 1973 to 
2011 SEER 18 database to examine the relationship between GBM cases in urban and 
rural areas, tumor size, treatment options, and survival.  The SEER Program provides a 
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cancer database, which is the premier source of cancer-specific and population statistics 
associated by age, race/ethnicity, year of diagnosis, and geographic areas in the United 
States.  Additionally, it is the only comprehensive source of population-based data in the 
United States that documents tumor size at diagnosis and survival data (SEER, 2013).  
The SEER 18 Registries of the NCI collects and analyzes cancer incidence, prevalence, 
and survival data from 18 population-based cancer registries covering approximately 
28% of the total U.S. population (SEER, 2013).  Refer to Table 9 in Chapter 3 for a 
complete listing of the registries.  While the entire United States is not represented in the 
SEER database, the coverage is broad enough to account for the various diverse 
populations throughout the United States (SEER, 2010). 
Using the SEER 18 database, cases were selected specific to this study that 
included all adults greater than 20 years old diagnosed with GBM in the United States 
between 1988 and 2011.  This selection resulted in 33,202 eligible cases.  Permission to 
view the selected cases was granted by both the Walden University IRB approval # 01-
28-14-0174231 and the SEER Program.   
Demographic information collected for this analysis included the following: a 
unique patient identifier, age, gender, race, marital status, registry location, location of 
residence categorized by either urban or rural area, median family income, educational 
level (< 9th grade, high school, or bachelor’s degree), GBM tumor size in millimeters, 
whether or not the patient underwent surgical resection of the brain tumor (yes/no), 
whether or not the patient underwent radiation therapy (yes/no), and survival time noted 
in months.  It should be noted that data for the adjuvant therapy of chemotherapy 
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administration were going to be obtained from the SEER database.  Unfortunately, these 
data were no longer included in the SEER database made available to the public.  This 
will be further explained in Chapter 5.  Since this was a retrospective study where de-
identified patient information was used, informed consent was not required.  
The study sample of 33,202 patients appears to exhibit appropriate external 
validity in that the sample consisted of patients representing all 18 registries of the SEER 
database.  Furthermore, the sample includes both males and females diagnosed with 
GBM as well as all races, 20 years and older, representing urban and rural areas.  It is 
worth noting that there are no studies to date that have examined the demographic 
variables of GBM from the geographic perspective of urban versus rural locations.  As 
described in the following results section, descriptive statistics appropriately examined 
the study sample, and inferential statistics explored the aforementioned research 
questions and associated hypotheses.   
Demographic Results 
Initially, a series of descriptive statistics was conducted on these data to 
summarize characteristics of the study population.  First, Figure 8 shows the number of 
GBM cases diagnosed from 1988 through 2011 in the United States.  In general, 
diagnosed cases have increased annually with a sharp spike in 2000. 
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Figure 8.  Glioblastoma multiforme cases diagnosed in the United States from the SEER data 
base, 1988-2011. 
 
The sample included 12,430 females (37.44%) and 20,772 males (62.56%).  As shown in 
the following table, the vast majority of the sample was white (91%), followed by black 
(5.14%) and other (4.19%).  Finally, less than 1% of respondents did not have valid data 
on race. 
Table 10 
 
Percent Distribution of Study Subjects by Race (N = 33,202) 
 
Category                                           N                                           % 
 
Black 1,706 5.14 
Other 1,391 4.19 
White                                          30,049 90.50 
Unknown      56 0.17 
Total                                            33,202 
 
Table 11 summarizes the descriptive statistics conducted focusing upon respondent age. 
As shown, a broad range in responses was found, with the majority of patients being 
between the ages of 50 and 74. 
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Table 11 
 
Frequency Distribution of Study Subjects by Age. (N = 33,202) 
 
Category                                            N                                         % 
 
20-24 years    215 0.65 
25-29 years    371 1.12 
30-34 years    520 1.57 
35-39 years    873 2.63 
40-44 years 1,545 4.65 
45-49 years 2,576 7.76 
50-54 years 3,586 10.80 
55-59 years 4,364 13.14 
60-64 years 4,771 14.37 
65-69 years 4,434 13.35 
70-74 years 4,134 12.45 
75-79 years 3,260 9.82 
80-84 years 1,816 5.47 
85+ years    737 2.22 
Total                                            33,202                                  100.00   
 
Table 12 summarizes the descriptive statistics conducted with relation to marital status at 
time of diagnosis.  Slightly over 76% of the sample was found to be married, with 
slightly over 9% being divorced.  Slightly over 13% of respondents were single/never 
married, with close to 1% being separated. 
Table 12 
 
Frequency Distribution of Study Subjects by Marital Status (N = 33,202) 
 
Category                                             N                                        % 
Divorced   3,134 9.44 
Married 25,308 76.22 
Separated      286 0.86 
Single (never married)   4,474 13.48  
Total                                              33,202   
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Table 13 summarizes from which registry location these data were derived.  As 
shown, a very wide range was found with regard to the source of these data, suggesting 
that while not a probability sample, these data are representative of a broad population of 
patients.  With respect to region, 29,140 (88.29%) patients lived in urban (metropolitan) 
regions, while 3,864 (11.71%) live in rural (nonmetropolitan) regions. 
Table 13 
 
Frequency Distribution of Study Subjects by Location of Registry 
 
Category                                                                        N                                           % 
 
Alaska Natives - 1992+       19 0.06 
Atlanta (Metropolitan) - 1975+  1,179 3.55 
California excluding SF/SJM/LA - 2000+  6,005 18.09 
Connecticut - 1973+  2,397 7.22 
Detroit (Metropolitan) - 1973+  2,213 6.67 
Greater Georgia - 2000+  1,681 5.06 
Hawaii - 1973+     418 1.26 
Iowa - 1973+  2,118 6.38 
Kentucky - 2000+  1,254 3.78 
Los Angeles - 1992+  3,476 10.47 
Louisiana - 2000+  1,214 3.66 
New Jersey - 2000+  2,843 8.56 
New Mexico - 1973+     809 2.44 
Rural Georgia - 1992+       61 0.18 
San Francisco-Oakland SMSA - 1973+  2,560 7.71 
San Jose-Monterey - 1992+  1,132 3.41 
Seattle (Puget Sound) - 1974+  2,690 8.10 
Utah - 1973+  1,133 3.41 
Total                                                                          33,202                                  100.00 
 
Table 14 summarizes the descriptive statistics conducted with regard to all continuous 
measures of interest included within the data.  This consisted of tumor size, median 
family income measured in $10,000s, the percentage of the population with less than a 
high school degree, the percentage with a bachelor's degree or above, survival (measured 
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in months), and year of diagnosis.  Mean scores were focused upon as a measure of 
central tendency for these measures, as mean and median scores were found to be very 
similar with the exception of survival time.  Mean tumor size is measured in millimeters 
and relates to a new measure that combined the two initial measures of tumor size after 
having removed all missing and invalid data.  Average tumor size was found to be close 
to 34 mm.  Next, with regard to median family income, this was found to be close to 
$73,000.  The percentage of individuals with less than a high school degree was found to 
be close to 15%, with the percentage having at least a bachelor's degree found to be close 
to 31%.  Mean survival time was close to 12 months with a median of 7 months. 
Table 14 
 
Frequency Distribution of Study Subjects by Continuous Measures 
 
Measure                                   Valid N       Mean        Median            SD          Min           Max 
 
Tumor Size (mm) 33202       33.553          36              37.418         0             989 
Family Inc. (in $10k) 33201         7.267            6.948         1.700         2.565        12.381 
% less than High School 33201       14.885          13.52           6.180         1.390   43.89 
% at least BA Degree 33201       30.591          29.61         10.226       45.90   63.94 
Survival (Months) 33176       11.824            7              18.361          0            287 
 
Additionally, Table 15 looks at the sociodemographic variables of race, marital status, 
educational level, age, and median family income by rural and urban regions. 
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Table 15 
 
Frequency Distribution of Study Subjects by Sociodemographic Characteristics 
 
Variables  Rural (N)   Rural %    Urban (N)   Urban %    Total 
 
Race 
     
  Black 126 7.39% 1580 92.61% 1706 
  White 3779 12.58% 26270 87.42% 30049 
  Other 155 11.14% 1236 88.86% 1391 
  Unknown 2 3.57% 54 96.43% 56 
  Total 4062 12.2% 29140 87.8% 33202 
 
Marital status 
     
  Single 392 8.76% 4082 91.24% 4474 
  Married 3286 12.98% 22022 87.02% 25308 
  Divorced 360 11.49% 2774 88.51% 3134 
  Separated 24 8.39% 262 91.61% 286 
 
Education level 
     
  Low – 64.22% – 69.55% – 
  Medium – 15.88% – 14.75% – 
  High – 18.97% – 32.21% – 
 
Age 
     
  < 50 635 10.41% 5465 89.59% 6100 
  51-70 2099 12.24% 15056 87.76% 17155 
  71-80 1018 13.77% 6376 86.23% 7394 
  > 80 310 12.14% 2243 87.86% 2553 
 
Median family 
income 
     
  < $50,000 1325 63.04% 777 36.96% 2102 
  $51,000 - $64,000 1908 17.40% 9060 82.60% 10968 
  > $65,000 828 4.11% 19303 95.89% 20131 
 
Finally, several new measures were constructed for the purpose of these analyses.  
With regard to surgical resection, 8,709 (26.23%) patients did not receive resection, while 
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24,493 (73.77%) did.  Regarding radiation, 8,075 (24.80%) patients did not receive 
radiation therapy, while 24,484 (75.20%) did.  
Research Questions and Hypotheses Results 
Research Question 1: Results 
Research Question 1: When comparing urban and rural patients with GBM, is 
there a significant difference in GBM tumor size at diagnosis? 
H01: When comparing urban and rural patients with GBM, there is no significant 
difference in GBM tumor size.  
H11: When comparing urban and rural patients with GBM, there is a significant 
difference in GBM tumor size. 
 In order to test the first research question, initially, measures of skewness and 
kurtosis indicated strong nonnormality with respect to tumor size.  However, the very 
large sample size present in this data set would make nonnormality less important with 
respect to an independent samples t test; for this reason, both a t test as well as a Mann-
Whitney U test was conducted in order to test this research question.  In these analyses, 
tumor size at the time of diagnosis was analyzed as the outcome measure of interest, with 
regional status included as the dichotomous predictor variable. 
 First, Table 16 summarizes the descriptive statistics associated with the Mann-
Whitney U test.  As shown, moderate differences were present when comparing the rank 
sums and expected values.  This test itself was found to achieve statistical significance, z 
= -2.632, p = .0085.  These results indicate that patients residing in rural areas had a 
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significantly larger mean tumor size as compared with those residing in urban regions.  
Therefore, the null hypothesis is rejected. 
Table 16 
 
Descriptive Statistics of Urban/Rural Areas Using the Mann-Whitney U test 
 
Category                     Valid N                  Ranksum                     Expected 
 
Urban 29140 4.794E8 4.809E8 
Rural 3864 65212919   63765660 
Combined 33004 5.446E8 5.446E8   
 
Next, Table 17 summarizes the descriptive statistics associated with the independent-
samples t test conducted. Again, these results indicate a higher mean tumor size with 
regard to individuals residing in non-metropolitan regions. The independent-samples  
t test also achieved significance, t (33002) =  -2.3722, p = .018.  Therefore, the null 
hypothesis is rejected. 
Table 17 
 
Descriptive Statistics of Urban/Rural Regions Using the Independent-Samples t-test 
 
Category                     Valid N                    Mean                              SD 
 
Urban 29140 33.391 .215 
Rural   3864 34.913   .682 
Combined 33004 33.569 .206 
Difference  -1.522 .641                                           
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Research Question 2: Results 
Research Question 2: When comparing urban and rural patients with GBM, is 
there a significant difference in the number of patients who experienced surgical 
resections? 
 H02: When comparing urban and rural patients with GBM, there is no significant 
difference in the number of patients who experienced surgical resections. 
 H12: When comparing urban and rural patients with GBM, there is a significant 
difference in the number of patients who experienced surgical resections. 
Initially, a new measure was created which consisted of a dummy measure of 
whether or not respondents had a surgical resection.  In the overall sample of 33,202 
patients, 24,493 (73.8%) had a surgical resection, while 8,709 did not (26.2%).  A chi-
square analysis was then conducted to determine if a significant association existed 
between these two measures.  First, Table 18 presents the cross tabulation conducted 
between these two measures.  As shown, no distinct relationship is apparent.  
Table 18 
 
Cross Tabulation Results Between Surgical Resection and Regional Status 
 
Region                                                     Resection 
 
Category                       No                            Yes                              Total 
 
Urban 7617 21523 29140 
Rural 1032 2832   3864 
Total 8649 24355 33004                                         
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Second, the chi-square analysis conducted in relation to this hypothesis also failed to 
achieve statistical significance, χ2 (1) = .5707, p = .450. Therefore, the null hypothesis is 
accepted. 
Research Question 3: Results 
Research Question 3: When comparing urban and rural patients with GBM, is 
there a significant difference in the number of patients who experienced the adjuvant 
therapies of radiation treatment and chemotherapy? 
 H03: When comparing urban and rural patients with GBM, there is no significant 
difference in the number of patients who experienced the adjuvant therapies of radiation 
treatment and chemotherapy. 
 H13: When comparing urban and rural patients with GBM, there is a significant 
difference in the number of patients who experienced the adjuvant therapies of radiation 
treatment and chemotherapy. 
For this research question, initially, a new variable was constructed which 
consisted of a dummy variable measuring whether patients received radiation treatment. 
This measure was coded 1 for patients that received any kind of radiation therapy 
including the categories of beam radiation, combination of beam with implants or 
isotopes, radiation NOS method or source not specified, radioactive implants, and 
radioisotopes, and was coded 0 in cases of no radiation, and missing if responses to this 
question were refused.  Out of this sample of 32,366 patients, it was found that 24,333 
(75.2%) patients received radiation therapy while 8,033 (24.8%) patients did not receive 
radiation therapy.  The use of radiation was slightly more common among patients 
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residing in urban regions compared to rural areas. The chi-square analysis conducted is 
found to achieve statistical significance, χ2 (1) = 18.3962, p < .001.  Therefore, the null 
hypothesis is rejected.  See Table 19.  
Table 19 
 
Frequency Distribution of Study Subjects Comparing Radiation Therapy by Region 
 
Region                                                     Radiation 
 
Category                          No                               Yes                              Total 
 
Urban 6987 (24.4%)      21596 (75.6%)          28583  
Rural 1046 (27.6%)       2737 (72.4%)           3783 
Total 8033 (24.8%) 24333 (75.2%)      32366                                         
 
Research Question 4: Results 
Research Question 4: When comparing urban and rural patients with GBM, is 
there a significant difference in survival rates? 
H04: When comparing urban and rural patients with GBM, there is no significant 
difference with survival rates. 
H14: When comparing urban and rural patients with GBM, there is a significant 
difference in survival rates. 
Of the overall sample of 33,176 patients, 4,056 (12.2%) rural patients survived 
10.3 months while 29,120 (87.8%) urban patients survived 12.04 months as seen in Table 
20.  
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Table 20 
 
Frequency Distribution of Study Subjects by Survival Time in Months 
  
Category                                      N                    Mean                     SD 
Rural   4,056    10.286 16.119 
Urban  29,120 12.039 18.642 
Total                                         33,176   
 
Survival data is commonly depicted with a Kaplan-Meier curve noted in Figure 10.  To 
further explore this fourth research question, a Cox regression was conducted in which 
region was used to predict survival time.  This analysis again incorporated a total of 
33,176 cases with the same number of failures and a total time at risk of 392,283 months. 
Urban region was found to achieve statistical significance, with a hazard ratio of .882 
(robust SE = .015), p < .001, 95% CI = [.853, .913].  Additionally, this regression model 
was found to achieve statistical significance, Wald χ2 (1) = 52.94, p < .001.  Therefore, 
the null hypothesis is rejected as noted in Figure 9.. 
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Figure 9.   Kaplan-Meier survival estimates for urban (metro) and rural (nonmetro)  
GBM patients. 
 
Research Question 5: Results 
 Research Question 5: In the study population of GBM patients, is there a 
significant difference in survival rates when controlling for region, race, age, sex, 
educational level, and median family income? 
H05: In the study population of GBM patients, when controlling for region, race, 
age, sex, educational level, and median family income, there is no significant difference 
in survival rates.  
H15: In the study population of GBM patients, when controlling for region, race, 
age, sex, educational level, and median family income, there is a significant difference in 
survival rates.  
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 In this analysis, the measures of region, race, age, gender, educational level, and 
median family income were included as predictors of the number of survival months. 
Since the data on the total number of survival months were found to be strongly 
positively skewed, a negative binomial regression was used for this analysis.  
Specifically, the predictors noted above included a dummy variable representing regional 
status, dummy variables representing blacks as well as individuals of other race and 
individuals whose race was unknown, a dummy variable representing females, along with 
age, the percentage of individuals with less than a high school education, the percentage 
with at least a bachelor’s degree, as well as median family income measured in $10,000s, 
which were all included as continuous measures. 
 The results of the analysis found statistical significance with respect to the effects 
of regional status, age, gender, and median family income.  Significantly longer survival 
time was associated with urban status, female patients, and higher median family income.  
Additionally, greater age was associated with significantly reduced survival time.  This 
overall regression model was found to achieve statistical significance, with a pseudo R2 
of .0302.  Therefore, the null hypothesis is rejected.  See Table 21. 
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Table 21 
 
Negative Binomial Regression Results When Controlling for Region, Race, Age, Gender, 
Education, and Family Income 
 
Variable                                        Coefficient                SE                           z                           p        
 
Urban Region .058               .020                        2.85                    0.004  
Race: Black - .050               .026                       -1.88                    0.060 
Race: Other .043               .029                        1.46                    0.143 
Race: Unknown .095               .140                        0.68                    0.500 
Age - .189               .002                     -83.65                    0.000 
Female .076               .012                        6.35                    0.000 
% Less than High School .001               .001                        1.14                    0.254 
% At Least BA - .001               .001                       -0.67                    0.501 
Median Family Income .035               .007                        5.28                    0.000 
Constant  3.692               .048                      76.31                    0.000   
 
Note. N = 33175; LR χ2(9) = 7005.49, p < .0001; Pseudo R2 = 0.0302; Log likelihood = -
112567.38; Likelihood-ratio test of α = 0: χ2(1) = 3.1E5, p >= χ2 < .001. 
 
Summary and Transition 
 This study examined if there were differences in tumor size, treatment options, 
and survival rates between rural and urban residents diagnosed with GBM.  With regard 
to tumor size, the results of this study indicated a significant difference in tumor size at 
diagnosis between rural and urban GBM cases; that is, rural GBM patients presented with 
significantly larger tumors at diagnosis.  Therefore, the null hypothesis was rejected.  
Treatment options of patients undergoing surgical resection, radiation therapy, and 
chemotherapy were explored.  There were no significant differences observed in rural 
and urban GBM patients undergoing surgical resections.  Therefore, the null hypothesis 
was accepted.  On the other hand, there were significant differences in urban GBM 
patients undergoing radiation therapy compared to their rural counterparts. Therefore, the 
null hypothesis was rejected.  It was also noted that the chemotherapy variable could not 
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be measured as it was removed from the SEER 18 database.  The survival rate of GBM 
patients in rural and urban areas was found to be statistically significant; that is, GBM 
patients in rural areas have a poorer survival rate than GBM patients in urban areas.  
Therefore the null hypothesis was rejected.  In the final analysis, the survival rate was 
examined in relationship to region, race, age, gender, educational level, and median 
family income.  Significantly longer survival times were noted with living in urban 
regions, being female, and higher median family income.  Additionally, greater age was 
associated with significantly reduced survival time.  The overall regression model was 
found to be statistically significant.  Thus, the null hypothesis was rejected. 
 Chapter 4 included the results of this quantitative, retrospective study that 
examined the differences in tumor size, treatment options, and survival rate in rural and 
urban patients diagnosed with GBM.  Chapter 5 will include a further discussion on the 
results by providing an interpretation of the observed findings, and how the findings 
relate to current literature and within the context of the proposed theoretical foundation. 
In Chapter 5, I will also outline the strengths and limitations of this study, as well as 
provide recommendations for future research.  Finally, in Chapter 5, I will discuss the 
potential impact for making positive social change. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
 The purpose of this quantitative, retrospective study was to determine if there 
were differences in tumor size, treatment options, and survival rates between rural and 
urban residents diagnosed with GBM.  Patients who receive a GBM diagnosis barely 
survive a year beyond the original diagnosis.  Studies have not identified any consistent 
links between possible risk factors and the development of GBM despite the rising 
incidence of GBM (Bondy et al., 2008; Connelly & Malkin, 2007; Gomes et al., 2011).  
While there is a plethora of research specific to GBM from environmental and genetic 
influences, very little research has examined GBM from a regional perspective. This 
project is unique in that examining patients diagnosed with GBM from an urban-rural 
perspective has never been done before, highlighting a significant gap in the literature.  
 Using the SEER 18 database covering the years 1973 to 2011, this study used 
secondary data sets of GBM cases reported between 1988 and 2011. Tumor size was 
measured in millimeters, treatment was evaluated by ascertaining the number of GBM 
patients who experienced surgical resection of their tumors and adjuvant therapies of 
radiation and chemotherapy, and survival rate was evaluated using Kaplan-Meier curves 
and Cox Regression analysis.  With a sample size of 33,202 cases, data were obtained 
and examined using descriptive and multivariable analyses of data with SPSS.  Using the 
Mann-Whitney U test and the independent samples t test, results showed statistically 
significant differences in tumor size at diagnosis in rural patients compared to urban 
patients (p = 0.0085; p = 0.018); that is, rural GBM patients had significantly larger 
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tumor size at diagnosis compared to urban GBM patients.  Furthermore, more urban 
GBM patients were treated with radiation compared to their rural counterparts (p < 
0.001).  Additionally, rural GBM patients had poorer survival rates than urban GBM 
patients (p< 0.001).  Finally, when controlling for region, race, age, gender, educational 
level, and median family income, a negative binomial regression analysis showed 
significantly longer survival time was associated with urban status, female patients, and 
higher median family income (Pseudo R2 = 0.0302; p < 0.0001).  Moreover, greater age 
was associated with significantly reduced survival time (Pseudo R2 = 0.0302; p < 
0.0001).  
Interpretation of the Findings 
 When comparing the results of this study to previous findings identified in the 
Literature Review found in Chapter 2, the descriptive data appear to confirm prior 
research.  However, as noted previously, this study was unique in that examining patients 
diagnosed with GBM from an urban-rural perspective has never been done before.  
Therefore, this study’s results provide new knowledge in the GBM arena outlined below. 
Descriptive Data 
 As discussed previously, while primary malignant brain tumors are rare in the 
United States compared to other types of cancer (American Cancer Society, 2012a), there 
is an increasing incidence of brain cancer reported for the last 3 decades (Deorah et al., 
2006).  Figure 9 in Chapter 4 showed an increase in GBM incidence from 1988 to 2011.  
Furthermore, while Aldape et al. (2003) found that GBMs are 1.6 times more common in 
men than women, this study found GBMs are 1.7 times more common in men than 
81 
 
 
women.  Additionally, as in the study by Ohgaki and Kleihues (2005), this study 
confirmed that glioblastomas are significantly higher among Whites as compared to 
Blacks, American Indians and Alaskan natives, and Asian-Pacific Islanders race groups.  
As in other peer-reviewed studies, the results of this study confirm that glioblastomas are 
more common in older adults, and increase with age with primary occurrence in adults 
from 45 to 70 years old (National Cancer Institute, 2012).  Finally, with regard to 
survival, the median survival time for a newly diagnosed GBM patient is approximately 1 
year (Aldape et al., 2003) compared to slightly less than 1 year in this study.   
Research Question 1: Tumor Size 
 In this study, I tested the hypotheses associated with the following research 
question: When comparing urban and rural patients with GBM, is there a significant 
difference in GBM tumor size at diagnosis? 
H01: When comparing urban and rural patients with GBM, there is no significant 
difference in GBM tumor size.  
H11: When comparing urban and rural patients with GBM, there is a significant 
difference in GBM tumor size. 
 In order to test this first research question, initially, measures of skewness and 
kurtosis indicated strong nonnormality with respect to tumor size.  However, the very 
large sample size present in this data set would make nonnormality less important with 
respect to an independent samples t test; for this reason, both a t test as well as a Mann-
Whitney U test were conducted in order to test this research question.  In these analyses, 
tumor size at the time of diagnosis was analyzed as the outcome measure of interest, with 
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regional status included as the dichotomous predictor variable.  Both tests showed 
statistically significant differences in tumor size in rural GBM patients compared to urban 
GBM patients (Mann-Whitney, p= 0.0085; independent samples t test, p= 0.018); that is, 
rural patients presented with larger GBM tumors than urban GBM patients.  This resulted 
in the rejection of the null hypothesis.  To date, no other studies have explored GBM 
tumor size from this urban-rural perspective.  Several studies have suggested that rurality 
is a risk factor in presenting with larger tumor size in other cancers including breast, lung, 
cervical, and prostate cancers (Obertova, Brown, Holmes, & Lawrenson, 2011; Smaliyte 
& Kurtinaitis, 2008; Westeel et al., 2007, Zhang, Bu, & Gao, 2013).  
Research Question 2: Surgical Resection 
 This study tested the hypotheses associated with the following research question: 
When comparing urban and rural patients with GBM, is there a significant difference in 
the number of patients who experienced surgical resections? 
 H02: When comparing urban and rural patients with GBM, there is no significant 
difference in the number of patients who experienced surgical resections. 
 H12: When comparing urban and rural patients with GBM, there is a significant 
difference in the number of patients who experienced surgical resections. 
 Initially, a new measure was created which consisted of a dummy measure of 
whether or not respondents had a surgical resection.  In the overall sample of 33,202 
patients, 24,493 (73.8%) had a surgical resection, while 8,709 did not (26.2%).  A chi-
square analysis was then conducted in order to determine whether a significant 
association existed between these two measures.  The chi-square analysis conducted in 
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relation to this hypothesis failed to achieve statistical significance, χ2 (1) = .5707, p  = 
.450.  Therefore, the null hypothesis was accepted; that is, there is no significant 
difference in the number of GBM patients who experienced surgical resection.  These 
findings are new and add to the current body of knowledge.  Research from the Glioma 
Outcomes Project demonstrated that patient age, functional status, and complete resection 
of the tumor were statistically significant prognostic indicators for patient survival (Laws 
et al., 2003).  However, complete surgical resection of the GBM tumor is impossible 
because of the hyper-vascularity and invasiveness of the tumor.  Therefore, near-total 
resection is done to decrease the tumor size, relieve intracranial pressure, and improve 
survival (Chandana et al., 2008).   
Research Question 3: Treatment Options 
 This study tested the hypotheses associated with the following research question: 
When comparing urban and rural patients with GBM, is there a significant difference in 
the number of patients who experienced the adjuvant therapies of radiation treatment and 
chemotherapy? 
 H03: When comparing urban and rural patients with GBM, there is no significant 
difference in the number of patients who experienced the adjuvant therapies of radiation 
treatment and chemotherapy. 
 H13: When comparing urban and rural patients with GBM, there is a 
significant difference in the number of patients who experienced the adjuvant therapies of 
radiation treatment and chemotherapy. 
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 It should be noted that data for the SEER database are routinely collected on 
cancer patients who undergo radiation treatments and chemotherapy administration.  
SEER has a rigorous methodology for ensuring the quality and accuracy of collected 
data.  Over the last decade, SEER database administrators have ascertained that data 
associated with chemotherapy administration are significantly under-reported.  For this 
reason, chemotherapy data were not included in the SEER database made available to the 
public.  Consequently, for this current study, the chemotherapy variable was not 
measured.  
Continuing with radiation treatments, for this research question, a new variable 
was constructed that consisted of a dummy variable measuring whether patients received 
radiation treatment.  This measure was coded 1 for patients who received any kind of 
radiation therapy including the categories of beam radiation, combination of beam with 
implants or isotopes, radiation NOS method or source not specified, radioactive implants, 
and radioisotopes, and was coded 0 in cases of no radiation, and missing if responses to 
this question were refused.  Out of this sample of 32,366 patients, it was found that 
24,333 patients received radiation therapy (75.2%) while 8,033 (24.8%) patients did not 
receive radiation therapy.  As shown in Table 18, the use of radiation was slightly more 
common among patients residing in urban regions compared to rural areas.  The chi-
square analysis conducted was found to achieve statistical significance, χ2 (1) = 18.3962, 
p < .001.  Therefore, the null hypothesis was rejected; that is, when comparing urban and 
rural patients, there is a significant difference in the number of GBM patients who 
experienced the adjuvant therapy of radiation treatments.  In other words, more urban 
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GBM patients undergo radiation therapy compared to their rural counterparts.  These 
findings are new and add to the current body of knowledge.  Prior to 2005, the standard 
of care for newly diagnosed GBM patients was surgical removal of the tumor (surgical 
resection) followed by radiation therapy (adjuvant radiotherapy).  The benefit of 
chemotherapy had not been well established.  However, in 2005, a landmark randomized 
trial demonstrated the overall survival benefit of adding chemotherapy identified as 
temozolomide  with radiation following maximal surgical resection of the tumor (Stupp 
et al., 2005).  As a result of this landmark study, and given the dismal prognosis 
associated with GBM diagnosis, multimodal aggressive therapy consisting of surgical 
resection of the tumor, local radiotherapy, and systemic chemotherapy is done in an 
attempt to prolong survival time.   
Research Question 4: Survival 
 This study tested the hypotheses associated with the following research question: 
When comparing urban and rural patients with GBM, is there a significant difference in 
survival rates? 
H04: When comparing urban and rural patients with GBM, there is no significant 
difference with survival rates. 
H14: When comparing urban and rural patients with GBM, there is a significant 
difference in survival rates. 
Of the overall sample of 33,176 patients, 4,056 (12.2%) rural patients survived 
10.3 months while 29,120 (87.8%) urban patients survived 12.04 months.  Survival data 
are commonly depicted with a Kaplan-Meier curve (refer to Figure 10).  To further 
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explore this fourth research question, a Cox regression was conducted in which region 
was used to predict survival time.  This analysis again incorporated a total of 33,176 
cases with the same number of failures and a total time at risk of 392,283 months.  Urban 
region was found to achieve statistical significance, with a hazard ratio of .882 (robust SE 
= .015), p < .001, 95% CI = [.853, .913].  Additionally, this regression model was found 
to achieve statistical significance, Wald χ2 (1) = 52.94, p < .001.  Therefore, the null 
hypothesis was rejected; that is, GBM patients who live in urban regions survive longer 
than GBM patients in rural areas.  This study is unique in that it is the first to demonstrate 
a significant relationship between poorer survival for rural GBM patients compared to 
their urban counterparts.  However, the prognosis for patients diagnosed with GBM 
remains poor despite ongoing therapeutic advancements (Stupp et al., 2005; Yuile et al., 
2006; Yabroff et al., 2012).  Median survival from initial diagnosis is, at best, 
approximately 1 year.  
Research Question 5: Survival With Controlled Variables 
 This study tested the hypotheses associated with the following research question: 
In the study population of GBM patients, is there a significant difference in survival rates 
when controlling for region, race, age, sex, educational level, and median family income? 
H05: In the study population of GBM patients, when controlling for region, race, 
age, sex, educational level, and median family income, there is no significant difference 
in survival rates.  
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H15: In the study population of GBM patients, when controlling for region, race, 
age, sex, educational level, and median family income, there is a significant difference in 
survival rates.  
 In this analysis, the measures of region, race, age, gender, educational level, and 
median family income were included as predictors of the number of survival months.  
Since the data on the total number of survival months were found to be strongly 
positively skewed and overly dispersed, a negative binomial regression was used for this 
analysis.  Skewness refers to the asymmetry of the data’s distribution.  When data are 
symmetrically distributed, data are not skewed, and the mean, median, and mode are the 
same.  Positively skewed data means that their distribution are asymmetric and the 
“mean” of the data is pulled towards larger numbers.  Since the data in this study are 
described as strongly positively skewed, the mean is pulled in the direction of extreme 
scores that are significantly large, and the mean is greater than the median and mode.  
Overdispersion of data means there is greater variability in a data set than would 
otherwise be expected; that is, the variance is larger than the mean.  
 When using negative binomial regression, dummy variables are created 
(Gerstman, 2008, p. 337).  For this study, the predictors noted above included a dummy 
variable representing regional status, dummy variables representing Blacks as well as 
individuals of other races and individuals whose race was unknown, a dummy variable 
representing females, along with age, the percentage of individuals with less than a high 
school education, the percentage with at least a bachelor’s degree as well as median 
family income measured in $10,000s, which were all included as continuous measures.  
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The results of the analysis found statistical significance with respect to the effects of 
regional status, age, gender, and median family income. Significantly longer survival 
time was associated with urban status, female patients, and higher median family income.  
Additionally, greater age was associated with significantly reduced survival time.  This 
overall regression model was found to achieve statistical significance, with a pseudo R2 = 
0 .0302.  Therefore, the null hypothesis was rejected.  Again, this study is unique in that it 
is the first to show a statistically significant relationship between survival and GBM 
patients living in urban versus rural regions, gender, family income, and age.  There have 
been studies that have examined significant prognostic factors for survival in primary 
brain tumors.  Results of these studies demonstrated that age is the single most significant 
prognostic factor for survival in patients diagnosed with primary brain tumors, especially 
when age is younger than 60 years (Chandana et al., 2008; Mineo et al., 2007).   
Theoretical Framework of the Study 
 The theoretical framework used for this study is based on the behavioral model of 
health services developed by Andersen (1995).  This framework has been applied in 
access to healthcare, determination of quality, and outcomes (Blustein & Weitzman, 
1995; Fryer et al., 1999; Love & Lundquist, 1995; Phillips et al., 2000).  Andersen’s 
framework is based on the assertion that late access to cancer diagnostic services for 
patients experiencing GBM may potentially lead to increased tumor size, decreased 
treatment options, and decreased survival rates.  Concerned with inequalities to medical 
care access, Andersen initiated studies on the concepts of access in 1968.  Andersen’s 
model suggests that people’s use of healthcare relies on their general predisposition 
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concerning health services, issues that enable or block utilization of services, and their 
inherent need to seek health care.  Andersen (1995) noted that the purpose of the initial 
measures of access was to identify situations that either promote access to health care 
services, or obstruct access to services.  By 1995, Andersen revised the original focus on 
access to a behavioral approach of health services use, recognizing that the use of health 
services should maintain and/or improve the health status of the population, both 
perceived by the population and/or evaluated by health professionals (Andersen, 
Davidson, & Ganz, 1994).  
Placing this study within the context of the theoretical foundation, study results 
suggest the following: (1) Significant predisposing characteristics are age, gender, and 
race; (2) Significant enabling resources are geographic regions of urban versus rural 
locations, location and availability of healthcare resources, and income level; (3) The 
individual need to access healthcare due to the sudden illness of GBM impacts the actual 
use of health services.  Given the preponderance of these factors suggest that delays in 
accessing healthcare resources result in larger tumor size, fewer treatment options, and 
poorer survival rates for rural GBM patients.  
Limitations of the Study 
 First, this study explored a cohort of patients diagnosed with GBM obtained from 
the SEER 18 database (National Cancer Institute, n.d.).  Since this study focused only on 
the subpopulation of adult patients diagnosed with GBM, there is an inherent sample 
bias.  Second, the potential presence of confounding conditions certainly posed a threat to 
internal validity of the study. Internal validity is decreased if the observed effect is caused 
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by uncontrolled conditions.  Third, since GBMs are most common in the elderly who 
have complex health issues, survival could be affected by potential confounding 
conditions other than the GBM itself.  Fourth, the SEER database reports only on cancer 
information and incidence.  It does not address lifestyle factors or causes of cancer.  Fifth, 
since the database covered a 23-year timeframe from 1988 to 2011, the migration of 
patients lost to follow-up could result in an overestimate or underestimate of study 
results.  With the GBM population, survival is usually 12 to 15 months or less from time 
of diagnosis.  Since SEER does follow all patients until death, and the survival rate for 
GBM patients is poor, the likelihood of losing patients to follow-up should be minimal.  
Sixth, while there are numerous definitions of rural and urban areas, this particular study 
was based exclusively on the SEER definitions of urban (metropolitan) and rural 
(nonmetropolitan regions) which ultimately affect the generalizability of results.  There is 
no single, universally accepted definition of rural.  However, counties are the most 
commonly used geographic component of rural definitions.  The advantages of using 
“counties” to describe urban from rural areas are that they are simple to understand and 
their boundaries are very stable over time. Additionally, many national health data sets 
use counties as a core geographic unit.  Finally, the SEER Extent of Disease was used to 
characterize tumor size, and treatment options of surgery, radiation therapy, and 
chemotherapy.  These definitions need to be considered when comparing to other studies 
that use other definitions of measurements.  Additionally, SEER database administrators 
ascertained that data associated with chemotherapy administration is significantly under-
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reported.  For this reason, chemotherapy data was not included in the SEER database 
made available to the public.  Unfortunately, this variable could not be evaluated. 
Recommendations 
 GBM is a lethal brain tumor with a terrible prognosis barely surviving a year 
beyond the original diagnosis (Holland, 2000).  While the results of this study provide 
new information that certainly adds to the current body of knowledge, additional areas of 
exploration are warranted.  Since the SEER 18 database contain registry data representing 
28% of the population in the United States, additional research should focus on other 
areas of the U.S. to further explore the relationship of urban versus rural residence and 
associated outcomes.  Future studies could also focus on study outcomes categorized by 
the different types of urban and rural regions utilized for this study.  Additional studies 
could also focus on survival of GBM patients and their proximity to cancer centers and/or 
large, regional hospital.  Finally, knowing the overall median survival of GBM patients of 
12 to 15 months from diagnosis, perhaps future research should focus on long-term 
survivors and the associated factors that differentiate them from the majority. 
Implications for Social Change 
 GBMs are a major public health problem with more than 10,000 new cases 
reported annually in the U.S. (Clarke, Butowski, & Chang, 2011; Wen & Kesari, 2008). 
Despite recent advances in the standard of care, GBM prognosis remains grim.  
Essentially, GBM is an incurable disease that ultimately leads to death within one year 
from diagnosis.  This study can significantly impact social change by identifying 
geographical variables associated with health outcomes of GBM patients thereby leading 
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to earlier detection and improved survival rates of individuals and populations.  This 
study also provides valuable information to lawmakers responsible for the creation of 
healthcare policy and the allocation of healthcare resources.  
Conclusion 
 GBM is a malignant brain neoplasm characterized by its destructive ability to 
invade healthy brain tissue at an accelerated rate (Holland, 2000).  Due to its lethality, 
patients diagnosed with GBM have a dismal prognosis, barely surviving a year beyond 
the original diagnosis.  For this reason, Holland has referred to GBM as “the terminator” 
(p. 6242).  Since the vast majority of patients with GBM die of their disease within a 
year, and very few have long-term survival, these particular tumors have drawn 
significant attention in the research world.  There is a plethora of research seeking to 
identify risk factors, genetic connections, immunological explanations, viral vectors, and 
novel therapeutic approaches focused on tricking the GBM tumor into submission and 
thereby improving survival.   
This quantitative, retrospective study collected data on all adult GBM patients 
diagnosed from 1988 to 2011, and the ultimate purpose was to determine if differences in 
tumor size, treatment options, and survival rate occurred in urban and rural GBM patients 
in the United States.  Results showed statistically significant differences in tumor size at 
diagnosis and radiation treatments in rural patients compared to urban patients, and rural 
GBM patients had poorer survival rates than urban GBM patients.  Finally, when 
controlling for region, race, age, gender, educational level, and median family income, 
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significantly longer survival time was associated with urban status, female patients, 
younger patients, and higher median family income.  
Every research attempt in the GBM field should be with guarded optimism in that 
we get one step closer to successfully treating this devastating disease.  For those patients 
and families who have faced this terminal condition, the hope is to live long enough until 
a cure is available.  Until that time comes, the research imperative in the GBM arena 
takes on a sense of urgency. 
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June 1982 - July 1985 
Staff Nurse 
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Concurrent Employment 
 
Sibley Memorial Hospital (Washington, DC)                                                                                                         
April 2001 – April 2003  
Patient Care Coordinator 
 
Georgetown University Medical Center (Washington, DC)                                                                          
April 1997 – April 2003 
Clinical Administrator 
       
Georgetown University (Washington, DC)                                                                                                             
August 1994 - June 1996 
Clinical Instructor, School Of Nursing  
• Hospital-Based Clinical Instructor for Medical-Surgical Nursing, Junior and 
Senior Levels. 
• Participated In Course Planning, Curriculum Development And Review. 
• Curriculum Development And Course Coordinator For Perioperative Clinical 
• Elective For Senior Nursing Students. 
 
Marymount University (Arlington, Virginia)                                                                                                        
August 1993 - August 1994 
Clinical Instructor, School of Nursing  
• Hospital-based clinical instructor for fundamental and medical-surgical 
nursing students. 
• Instruction in mathematical concepts for drug calculations. 
• Participation in course planning, curriculum development and review. 
• Advisor for 20 nursing students in various phases of the nursing curriculum. 
 
